
-DOCSTART- -X- -X- O

Ceramide	NNP	O	O
is	VBZ	O	O
an	DT	O	O
important	JJ	O	O
regulatory	JJ	O	O
molecule	NN	O	O
implicated	VBN	O	O
in	IN	O	O
a	DT	O	O
variety	NN	O	O
of	IN	O	O
biological	JJ	O	O
processes	NNS	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
stress	NN	O	O
and	CC	O	O
cytokines	NNS	O	O
.	.	O	O

To	TO	O	O
understand	VB	O	O
the	DT	O	O
signal	JJ	O	O
transduction	NN	O	O
pathway	NN	O	O
of	IN	O	O
ceramide	NN	O	O
to	TO	O	O
the	DT	O	O
nucleus	NN	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
examined	VBD	O	O
whether	IN	O	O
C2-ceramide	NNP	O	O
,	,	O	O
a	DT	O	O
cell	NN	O	O
permeable	JJ	O	O
ceramide	NN	O	O
,	,	O	O
activates	VBZ	O	O
c-fos	JJ	O	O
serum	NN	O	O
response	NN	O	O
element	NN	O	O
(	(	O	O
SRE	NNP	O	O
)	)	O	O
.	.	O	O

Treatment	NN	O	O
of	IN	O	O
Rat-2	NNP	O	O
fibroblast	NN	O	O
cells	NNS	O	O
with	IN	O	O
C2-ceramide	NNP	O	O
caused	VBD	O	O
the	DT	O	O
stimulation	NN	O	O
of	IN	O	O
c-fos	JJ	O	O
SRE-dependent	JJ	O	O
reporter	NN	O	O
gene	NN	O	O
activity	NN	O	O
in	IN	O	O
a	DT	O	O
dose-	JJ	O	O
and	CC	O	O
time-dependent	JJ	O	O
manner	NN	O	O
by	IN	O	O
transient	JJ	O	O
transfection	NN	O	O
analysis	NN	O	O
.	.	O	O

Next	JJ	O	O
,	,	O	O
we	PRP	O	O
examined	VBD	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
Rho	NNP	O	O
family	NN	O	O
GTPases	VBZ	O	O
in	IN	O	O
the	DT	O	O
ceramide-induced	JJ	O	O
signalling	NN	O	O
to	TO	O	O
SRE	NNP	O	O
activation	NN	O	O
.	.	O	O

By	IN	O	O
reporter	NN	O	O
gene	NN	O	O
analysis	NN	O	O
following	VBG	O	O
transient	JJ	O	O
transfections	NNS	O	O
with	IN	O	O
various	JJ	O	O
plasmids	NNS	O	O
expressing	VBG	O	O
a	DT	O	O
dominant	JJ	O	O
negative	JJ	O	O
mutant	JJ	O	O
form	NN	O	O
of	IN	O	O
Cdc42	NNP	O	O
,	,	O	O
Rac1	NNP	O	O
or	CC	O	O
RhoA	NNP	O	O
,	,	O	O
C2-ceramide-induced	NNP	O	O
SRE	NNP	O	O
activation	NN	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
selectively	RB	O	O
repressed	VBN	O	O
by	IN	O	O
pEXV-RacN17	JJ	O	O
encoding	VBG	O	O
a	DT	O	O
dominant	JJ	O	O
negative	JJ	O	O
mutant	NN	O	O
of	IN	O	O
Rac1	NNP	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
Rac	NNP	O	O
activity	NN	O	O
is	VBZ	O	O
essential	JJ	O	O
for	IN	O	O
the	DT	O	O
signalling	VBG	O	O
cascade	NN	O	O
of	IN	O	O
ceramide	NN	O	O
to	TO	O	O
the	DT	O	O
nucleus	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
further	JJ	O	O
study	NN	O	O
to	TO	O	O
analyse	VB	O	O
the	DT	O	O
downstream	NN	O	O
mediator	NN	O	O
of	IN	O	O
Rac	NNP	O	O
in	IN	O	O
the	DT	O	O
ceramide-signalling	JJ	O	O
pathway	NN	O	O
,	,	O	O
we	PRP	O	O
observed	VBD	O	O
that	IN	O	O
either	DT	O	O
pretreatment	NN	O	O
with	IN	O	O
mepacrine	NN	O	O
,	,	O	O
a	DT	O	O
potent	NN	O	O
and	CC	O	O
specific	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
phospholipase	NN	O	O
A2	NNP	O	O
,	,	O	O
or	CC	O	O
co-transfection	NN	O	O
with	IN	O	O
antisense	JJ	O	O
cytosolic	JJ	O	O
phospholipase	NN	O	O
A2	NNP	O	O
(	(	O	O
cPLA2	NN	O	O
)	)	O	O
oligonucleotide	NN	O	O
repressed	VBD	O	O
the	DT	O	O
C2-ceramide-induced	NNP	O	O
SRE	NNP	O	O
activation	NN	O	O
selectively	RB	O	O
,	,	O	O
implying	VBG	O	O
a	DT	O	O
critical	JJ	O	O
role	NN	O	O
of	IN	O	O
cPLA2	NN	O	O
in	IN	O	O
C2-ceramide-induced	NNP	O	O
signalling	VBG	O	O
to	TO	O	O
nucleus	VB	O	O
.	.	O	O

Consistent	JJ	O	O
with	IN	O	O
these	DT	O	O
results	NNS	O	O
,	,	O	O
the	DT	O	O
translocation	NN	O	O
of	IN	O	O
cPLA2	NN	O	O
protein	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
release	NN	O	O
of	IN	O	O
arachidonic	JJ	O	B-PRODUCT-OF
acid	NN	O	I-PRODUCT-OF
,	,	O	O
a	DT	O	O
principal	JJ	O	O
product	NN	O	O
of	IN	O	O
phospholipase	NN	O	B-enzyme
A2	NNP	O	I-enzyme
,	,	O	O
was	VBD	O	O
rapidly	RB	O	O
induced	VBN	O	O
by	IN	O	O
the	DT	O	O
addition	NN	O	O
of	IN	O	O
C2-ceramide	NNP	O	O
in	IN	O	O
a	DT	O	O
Rac-dependent	JJ	O	O
manner	NN	O	O
.	.	O	O

Together	RB	O	O
,	,	O	O
our	PRP$	O	O
findings	NNS	O	O
suggest	VBP	O	O
the	DT	O	O
critical	JJ	O	O
role	NN	O	O
of	IN	O	O
'Rac	FW	O	O
and	CC	O	O
subsequent	JJ	O	O
activation	NN	O	O
of	IN	O	O
phospholipase	NN	O	O
A2	NNP	O	O
'	''	O	O
in	IN	O	O
ceramide-signalling	NN	O	O
to	TO	O	O
nucleus	VB	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Local	JJ	O	O
application	NN	O	O
of	IN	O	O
selective	JJ	O	O
serotonin	NNS	O	O
reuptake	VBP	O	O
inhibitors	NNS	O	O
,	,	O	O
fluvoxamine	NN	O	O
and	CC	O	O
citalopram	NN	O	O
,	,	O	O
prolonged	VBD	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
exogenously	RB	O	O
administered	VBN	O	O
serotonin	NN	O	O
(	(	O	O
5-HT	JJ	O	O
)	)	O	O
in	IN	O	O
both	CC	O	O
the	DT	O	O
dentate	NN	O	O
gyrus	NN	O	O
and	CC	O	O
CA3	NNP	O	O
region	NN	O	O
of	IN	O	O
the	DT	O	O
dorsal	NN	O	O
hippocampus	NN	O	O
,	,	O	O
as	IN	O	O
measured	VBN	O	O
using	VBG	O	O
in	IN	O	O
vivo	JJ	O	O
chronoamperometry	NN	O	O
.	.	O	O

These	DT	O	O
effects	NNS	O	O
were	VBD	O	O
abolished	VBN	O	O
in	IN	O	O
rats	NNS	O	O
pretreated	VBN	O	O
with	IN	O	O
5,7-dihydroxytryptamine	JJ	O	O
.	.	O	O

The	DT	O	O
NE	NNP	O	O
uptake	JJ	O	O
inhibitors	NNS	O	O
,	,	O	O
desipramine	NN	O	O
and	CC	O	O
protriptyline	NN	O	O
,	,	O	O
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
the	DT	O	O
5-HT	JJ	O	O
signal	NN	O	O
in	IN	O	O
the	DT	O	O
CA3	NNP	O	O
region	NN	O	O
,	,	O	O
but	CC	O	O
prolonged	VBD	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
5-HT	JJ	O	O
in	IN	O	O
the	DT	O	O
dentate	NN	O	O
gyrus	NN	O	O
;	:	O	O
this	DT	O	O
effect	NN	O	O
was	VBD	O	O
absent	NN	O	O
in	IN	O	O
rats	NNS	O	O
pretreated	VBN	O	O
with	IN	O	O
6-hydroxydopamine	JJ	O	O
.	.	O	O

From	IN	O	O
these	DT	O	O
data	NNS	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
inferred	VBN	O	O
that	IN	O	O
both	DT	O	O
the	DT	O	O
SERT	NNP	O	B-enzyme
and	CC	O	O
NET	NNP	O	B-enzyme
contribute	NN	O	O
to	TO	O	O
the	DT	O	O
active	JJ	O	O
clearance	NN	O	O
of	IN	O	O
exogenously	RB	O	O
applied	VBN	O	O
5-HT	JJ	O	B-SUBSTRATE
in	IN	O	O
the	DT	O	O
dentate	NN	O	O
gyrus	NN	O	O
.	.	O	O

In	IN	O	O
another	DT	O	O
experiment	NN	O	O
,	,	O	O
cyanopindolol	NN	O	O
,	,	O	O
an	DT	O	O
antagonist	NN	O	O
of	IN	O	O
the	DT	O	O
serotonin	JJ	O	O
terminal	JJ	O	O
autoreceptor	NN	O	O
,	,	O	O
also	RB	O	O
prolonged	VBD	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
5-HT	JJ	O	O
from	IN	O	O
the	DT	O	O
CA3	NNP	O	O
region	NN	O	O
.	.	O	O

These	DT	O	O
and	CC	O	O
other	JJ	O	O
data	NNS	O	O
have	VBP	O	O
generated	VBN	O	O
a	DT	O	O
working	JJ	O	O
hypothesis	NN	O	O
that	IN	O	O
activation	NN	O	O
of	IN	O	O
the	DT	O	O
terminal	JJ	O	O
serotonin	NN	O	B-enzyme
autoreceptor	NN	O	I-enzyme
enhances	VBZ	O	O
the	DT	O	O
kinetics	NNS	O	O
of	IN	O	O
5-HT	JJ	O	B-SUBSTRATE
uptake	NN	O	O
through	IN	O	O
an	DT	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
serotonin	NN	O	B-enzyme
transporter	NN	O	I-enzyme
.	.	O	O

-DOCSTART- -X- -X- O

cDNA	NN	O	O
encoding	VBG	O	O
a	DT	O	O
novel	JJ	O	O
phosphodiesterase	NN	O	O
(	(	O	O
PDE	NNP	O	O
)	)	O	O
was	VBD	O	O
isolated	VBN	O	O
from	IN	O	O
a	DT	O	O
human	JJ	O	O
fetal	NN	O	O
lung	NN	O	O
cDNA	NN	O	O
library	NN	O	O
and	CC	O	O
designated	VBN	O	O
PDE10A	NNP	O	O
.	.	O	O

The	DT	O	O
deduced	JJ	O	O
amino	NN	O	O
acid	NN	O	O
sequence	NN	O	O
contains	VBZ	O	O
779	CD	O	O
amino	NN	O	O
acids	NNS	O	O
,	,	O	O
including	VBG	O	O
a	DT	O	O
putative	JJ	O	O
cGMP	NN	O	O
binding	VBG	O	O
sequence	NN	O	O
in	IN	O	O
the	DT	O	O
amino-terminal	JJ	O	O
portion	NN	O	O
of	IN	O	O
the	DT	O	O
molecule	NN	O	O
and	CC	O	O
a	DT	O	O
catalytic	JJ	O	O
domain	NN	O	O
that	WDT	O	O
is	VBZ	O	O
16-47	JJ	O	O
%	NN	O	O
identical	JJ	O	O
in	IN	O	O
amino	JJ	O	O
acid	JJ	O	O
sequence	NN	O	O
to	TO	O	O
those	DT	O	O
of	IN	O	O
other	JJ	O	O
PDE	NNP	O	O
families	NNS	O	O
.	.	O	O

Recombinant	JJ	O	O
PDE10A	NNP	O	B-enzyme
transfected	VBD	O	O
and	CC	O	O
expressed	VBD	O	O
in	IN	O	O
COS-7	NNP	O	O
cells	NNS	O	O
hydrolyzed	VBD	O	O
cAMP	NN	O	B-SUBSTRATE
and	CC	O	O
cGMP	NN	O	B-SUBSTRATE
with	IN	O	O
Km	NNP	O	O
values	NNS	O	O
of	IN	O	O
0.26	CD	O	O
and	CC	O	O
7.2	CD	O	O
microM	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
and	CC	O	O
Vmax	NNP	O	O
with	IN	O	O
cGMP	NN	O	B-SUBSTRATE
was	VBD	O	O
almost	RB	O	O
twice	RB	O	O
that	IN	O	O
with	IN	O	O
cAMP	NN	O	B-SUBSTRATE
.	.	O	O

Of	IN	O	O
the	DT	O	O
PDE	NNP	O	B-enzyme
inhibitors	NNS	O	O
tested	VBD	O	O
,	,	O	O
dipyridamole	NN	O	O
was	VBD	O	O
most	RBS	O	O
effective	JJ	O	O
,	,	O	O
with	IN	O	O
IC50	NNP	O	O
values	NNS	O	O
of	IN	O	O
1.2	CD	O	O
and	CC	O	O
0.45	CD	O	O
microM	NN	O	O
for	IN	O	O
inhibition	NN	O	O
of	IN	O	O
cAMP	NN	O	B-SUBSTRATE
and	CC	O	O
cGMP	NN	O	B-SUBSTRATE
hydrolysis	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

cGMP	NN	O	O
inhibited	VBD	O	O
hydrolysis	NN	O	O
of	IN	O	O
cAMP	NN	O	O
,	,	O	O
and	CC	O	O
cAMP	NN	O	O
inhibited	VBN	O	O
cGMP	JJ	O	O
hydrolysis	NN	O	O
with	IN	O	O
IC50	NNP	O	O
values	NNS	O	O
of	IN	O	O
14	CD	O	O
and	CC	O	O
0.39	CD	O	O
microM	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
PDE10A	NNP	O	O
exhibited	VBD	O	O
properties	NNS	O	O
of	IN	O	O
a	DT	O	O
cAMP	NN	O	O
PDE	NNP	O	O
and	CC	O	O
a	DT	O	O
cAMP-inhibited	JJ	O	O
cGMP	NN	O	O
PDE	NNP	O	O
.	.	O	O

PDE10A	NNP	O	O
transcripts	NNS	O	O
were	VBD	O	O
particularly	RB	O	O
abundant	JJ	O	O
in	IN	O	O
the	DT	O	O
putamen	NNS	O	O
and	CC	O	O
caudate	VB	O	O
nucleus	JJ	O	O
regions	NNS	O	O
of	IN	O	O
brain	NN	O	O
and	CC	O	O
in	IN	O	O
thyroid	NN	O	O
and	CC	O	O
testis	NN	O	O
,	,	O	O
and	CC	O	O
in	IN	O	O
much	JJ	O	O
lower	JJR	O	O
amounts	NNS	O	O
in	IN	O	O
other	JJ	O	O
tissues	NNS	O	O
.	.	O	O

The	DT	O	O
PDE10A	NNP	O	O
gene	NN	O	O
was	VBD	O	O
located	VBN	O	O
on	IN	O	O
chromosome	NN	O	O
6q26	CD	O	O
by	IN	O	O
fluorescent	NN	O	O
in	IN	O	O
situ	JJ	O	O
hybridization	NN	O	O
analysis	NN	O	O
.	.	O	O

PDE10A	NNP	O	O
represents	VBZ	O	O
a	DT	O	O
new	JJ	O	O
member	NN	O	O
of	IN	O	O
the	DT	O	O
PDE	NNP	O	O
superfamily	RB	O	O
,	,	O	O
exhibiting	VBG	O	O
unique	JJ	O	O
kinetic	JJ	O	O
properties	NNS	O	O
and	CC	O	O
inhibitor	NN	O	O
sensitivity	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Tetrahydrobiopterin	NNP	O	O
[	NNP	O	O
(	(	O	O
6R	CD	O	O
)	)	O	O
-5,6,7,8-tetrahydro-L-biopterin	NN	O	O
,	,	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
]	NN	O	O
is	VBZ	O	O
one	CD	O	O
of	IN	O	O
several	JJ	O	O
cofactors	NNS	O	O
of	IN	O	O
nitric	JJ	O	O
oxide	NN	O	O
synthases	NNS	O	O
(	(	O	O
EC	NNP	O	O
1.14.13.39	CD	O	O
)	)	O	O
.	.	O	O

Here	RB	O	O
we	PRP	O	O
compared	VBN	O	O
the	DT	O	O
action	NN	O	O
of	IN	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-substituted	VBN	O	O
derivatives	NNS	O	O
on	IN	O	O
recombinant	JJ	O	O
rat	NN	O	O
neuronal	JJ	O	O
nitric	JJ	O	O
oxide	IN	O	O
synthase	NN	O	O
with	IN	O	O
their	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
dihydropteridine	NN	O	O
reductase	NN	O	O
(	(	O	O
EC	NNP	O	O
1.6.99.7	CD	O	O
)	)	O	O
and	CC	O	O
phenylalanine	JJ	O	O
hydroxylase	NN	O	O
(	(	O	O
EC	NNP	O	O
1.14.16.1	CD	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
well-studied	JJ	O	O
classical	JJ	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin-dependent	NN	O	O
reactions	NNS	O	O
.	.	O	O

H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
substituted	VBN	O	O
at	IN	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
with	IN	O	O
methyl	NN	O	O
,	,	O	O
hydroxymethyl	NN	O	O
,	,	O	O
formyl	NN	O	O
and	CC	O	O
acetyl	NN	O	O
groups	NNS	O	O
were	VBD	O	O
used	VBN	O	O
.	.	O	O

Substitution	NN	O	O
at	IN	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
occurs	VBZ	O	O
at	IN	O	O
a	DT	O	O
position	NN	O	O
critical	JJ	O	O
to	TO	O	O
the	DT	O	O
redox	JJ	O	O
cycle	NN	O	O
of	IN	O	O
the	DT	O	O
cofactor	NN	O	O
in	IN	O	O
phenylalanine	JJ	O	O
hydroxylase/dihydropteridine	NN	O	O
reductase	NN	O	O
.	.	O	O

We	PRP	O	O
also	RB	O	O
included	VBD	O	O
N	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
'-methyl	CD	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
,	,	O	O
a	DT	O	O
derivative	JJ	O	O
substituted	VBN	O	O
at	IN	O	O
a	DT	O	O
position	NN	O	O
not	RB	O	O
directly	RB	O	O
involved	VBN	O	O
in	IN	O	O
redox	NN	O	O
cycling	NN	O	O
,	,	O	O
as	IN	O	O
a	DT	O	O
control	NN	O	O
.	.	O	O

As	IN	O	O
compared	VBN	O	O
with	IN	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-methyl	NN	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
,	,	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-formyl	NN	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
bound	NN	O	O
with	IN	O	O
twice	RB	O	O
the	DT	O	O
capacity	NN	O	O
but	CC	O	O
stimulated	VBD	O	O
nitric	JJ	O	O
oxide	RB	O	O
synthase	NN	O	O
to	TO	O	O
a	DT	O	O
lesser	JJR	O	O
extent	NN	O	O
.	.	O	O

Depending	VBG	O	O
on	IN	O	O
the	DT	O	O
substituent	NN	O	O
used	VBN	O	O
,	,	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-substituted	VBN	O	O
derivatives	NNS	O	O
were	VBD	O	O
redox-active	JJ	O	O
:	:	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-methyl-	NN	O	O
and	CC	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-hydroxyl	NN	O	O
methyl	NN	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-formyl-	NN	O	O
and	CC	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-acetyl	NN	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
,	,	O	O
reduced	VBD	O	O
2,6-dichlorophenol	JJ	O	O
indophenol	NN	O	O
.	.	O	O

N	NNP	O	B-SUBSTRATE
(	(	O	O
5	CD	O	O
)	)	O	O
-Substituted	VBN	O	O
H	NNP	O	I-SUBSTRATE
(	(	O	I-SUBSTRATE
4	CD	O	I-SUBSTRATE
)	)	O	I-SUBSTRATE
biopterin	NN	O	I-SUBSTRATE
derivatives	NNS	O	O
were	VBD	O	O
not	RB	O	O
oxidized	VBN	O	O
to	TO	O	O
products	NNS	O	O
serving	VBG	O	O
as	IN	O	O
substrates	NNS	O	O
for	IN	O	O
dihydropteridine	JJ	O	B-enzyme
reductase	NN	O	I-enzyme
and	CC	O	O
,	,	O	O
depending	VBG	O	O
on	IN	O	O
the	DT	O	O
substituent	NN	O	O
,	,	O	O
were	VBD	O	O
competitive	JJ	O	O
inhibitors	NNS	O	O
of	IN	O	O
phenylalanine	JJ	O	O
hydroxylase	NN	O	O
:	:	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-methyl-	NN	O	O
and	CC	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-hydroxymethyl	NN	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
inhibited	VBN	O	O
phenylalanine	JJ	O	O
hydroxylase	NN	O	O
,	,	O	O
whereas	JJ	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-formyl-	NN	O	O
and	CC	O	O
N	NNP	O	O
(	(	O	O
5	CD	O	O
)	)	O	O
-acetyl	NN	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
demonstrate	NN	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
stimulation	NN	O	O
of	IN	O	O
phenylalanine	JJ	O	O
hydroxylase	NN	O	O
and	CC	O	O
nitric	JJ	O	O
oxide	NN	O	O
synthase	NN	O	O
by	IN	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
.	.	O	O

They	PRP	O	O
are	VBP	O	O
compatible	JJ	O	O
with	IN	O	O
a	DT	O	O
novel	NN	O	O
,	,	O	O
non-classical	JJ	O	O
,	,	O	O
redox-active	JJ	O	O
contribution	NN	O	O
of	IN	O	O
H	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
biopterin	NN	O	O
to	TO	O	O
the	DT	O	O
catalysis	NN	O	O
of	IN	O	O
the	DT	O	O
nitric	JJ	O	O
oxide	JJ	O	O
synthase	NN	O	O
reaction	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Endogenously	RB	O	O
produced	VBN	O	O
asymmetrically	RB	O	O
methylated	VBN	O	O
arginine	NN	O	O
residues	NNS	O	O
are	VBP	O	O
competitive	JJ	O	O
inhibitors	NNS	O	O
of	IN	O	O
all	DT	O	O
three	CD	O	O
isoforms	NNS	O	O
of	IN	O	O
nitric	JJ	O	O
oxide	JJ	O	O
synthase	NN	O	O
(	(	O	O
NOS	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
enzyme	JJ	O	O
dimethylarginine	NN	O	B-enzyme
dimethylaminohydrolase	NN	O	I-enzyme
(	(	O	O
DDAH	NNP	O	B-enzyme
)	)	O	O
specifically	RB	O	O
hydrolyzes	VBZ	O	O
these	DT	O	O
asymmetrically	RB	O	O
methylated	VBN	O	O
arginine	NN	O	B-SUBSTRATE
residues	NNS	O	O
to	TO	O	O
citrulline	VB	O	O
and	CC	O	O
methylamines	NNS	O	O
.	.	O	O

Previously	RB	O	O
we	PRP	O	O
have	VBP	O	O
proposed	VBN	O	O
that	IN	O	O
regulation	NN	O	O
of	IN	O	O
asymmetric	JJ	O	O
methylarginine	NN	O	B-SUBSTRATE
concentration	NN	O	O
by	IN	O	O
DDAH	NNP	O	B-enzyme
may	MD	O	O
provide	VB	O	O
a	DT	O	O
novel	JJ	O	O
mechanism	NN	O	O
for	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
NOS	NNP	O	O
activity	NN	O	O
in	IN	O	O
vivo	NN	O	O
.	.	O	O

Recently	RB	O	O
we	PRP	O	O
reported	VBD	O	O
the	DT	O	O
cloning	NN	O	O
of	IN	O	O
human	JJ	O	O
DDAH	NNP	O	O
and	CC	O	O
identified	VBD	O	O
a	DT	O	O
novel	JJ	O	O
human	JJ	O	O
DDAH	NNP	O	O
isoform	NN	O	O
(	(	O	O
DDAH	NNP	O	O
I	PRP	O	O
and	CC	O	O
DDAH	NNP	O	O
II	NNP	O	O
,	,	O	O
respectively	RB	O	O
)	)	O	O
.	.	O	O

Here	RB	O	O
we	PRP	O	O
report	VBP	O	O
that	IN	O	O
the	DT	O	O
DDAH1	NNP	O	O
gene	NN	O	O
maps	NNS	O	O
to	TO	O	O
chromosome	VB	O	O
1p22	CD	O	O
and	CC	O	O
confirm	VB	O	O
that	DT	O	O
DDAH2	NNP	O	O
maps	NNS	O	O
to	TO	O	O
the	DT	O	O
MHC	NNP	O	O
III	NNP	O	O
region	NN	O	O
of	IN	O	O
chromosome	NN	O	O
6p21.3	CD	O	O
.	.	O	O

Extensive	JJ	O	O
analysis	NN	O	O
of	IN	O	O
the	DT	O	O
distribution	NN	O	O
of	IN	O	O
DDAH1	NNP	O	O
and	CC	O	O
DDAH2	NNP	O	O
mRNA	NN	O	O
in	IN	O	O
50	CD	O	O
human	JJ	O	O
tissues	NNS	O	O
indicates	VBZ	O	O
differential	JJ	O	O
expression	NN	O	O
of	IN	O	O
DDAH	NNP	O	O
isoforms	NNS	O	O
in	IN	O	O
brain	NN	O	O
regions	NNS	O	O
,	,	O	O
in	IN	O	O
immune	JJ	O	O
cells	NNS	O	O
,	,	O	O
and	CC	O	O
during	IN	O	O
development	NN	O	O
.	.	O	O

DDAH2	NNP	O	O
expression	NN	O	O
predominates	NNS	O	O
in	IN	O	O
highly	RB	O	O
vascularized	JJ	O	O
tissues	NNS	O	O
that	WDT	O	O
express	VBP	O	O
the	DT	O	O
endothelial	JJ	O	O
NOS	NNP	O	O
isoform	NN	O	O
and	CC	O	O
in	IN	O	O
immune	JJ	O	O
tissues	NNS	O	O
that	WDT	O	O
can	MD	O	O
express	VB	O	O
iNOS	NN	O	O
.	.	O	O

Whereas	NNP	O	O
DDAH2	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
at	IN	O	O
relatively	RB	O	O
high	JJ	O	O
levels	NNS	O	O
in	IN	O	O
all	DT	O	O
fetal	JJ	O	O
tissues	NNS	O	O
examined	VBN	O	O
,	,	O	O
DDAH1	NNP	O	O
expression	NN	O	O
varies	VBZ	O	O
little	RB	O	O
between	IN	O	O
fetal	JJ	O	O
and	CC	O	O
adult	JJ	O	O
tissues	NNS	O	O
.	.	O	O

The	DT	O	O
chromosomal	JJ	O	O
localization	NN	O	O
of	IN	O	O
the	DT	O	O
DDAHs	NNP	O	O
is	VBZ	O	O
consistent	JJ	O	O
with	IN	O	O
gene	NN	O	O
duplication	NN	O	O
,	,	O	O
and	CC	O	O
consistent	JJ	O	O
with	IN	O	O
this	DT	O	O
,	,	O	O
comparison	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
structures	VBZ	O	O
indicates	VBZ	O	O
that	IN	O	O
the	DT	O	O
intron/exon	JJ	O	O
organization	NN	O	O
is	VBZ	O	O
highly	RB	O	O
conserved	VBN	O	O
.	.	O	O

Phylogenetic	JJ	O	O
analysis	NN	O	O
of	IN	O	O
DDAH	NNP	O	O
sequences	NNS	O	O
from	IN	O	O
diverse	JJ	O	O
species	NNS	O	O
suggests	VBZ	O	O
that	IN	O	O
DDAH	NNP	O	O
gene	NN	O	O
duplication	NN	O	O
occurred	VBD	O	O
prior	RB	O	O
to	TO	O	O
the	DT	O	O
emergence	NN	O	O
of	IN	O	O
bony	NN	O	O
fish	VB	O	O
some	DT	O	O
400	CD	O	O
million	CD	O	O
years	NNS	O	O
ago	RB	O	O
.	.	O	O

Overall	JJ	O	O
the	DT	O	O
data	NN	O	O
suggest	NN	O	O
that	IN	O	O
DDAH2	NNP	O	O
may	MD	O	O
be	VB	O	O
the	DT	O	O
more	RBR	O	O
ancient	NN	O	O
of	IN	O	O
the	DT	O	O
two	CD	O	O
genes	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Fumarate	NNP	O	B-enzyme
reductase	NN	O	I-enzyme
(	(	O	O
FRD	NNP	O	B-enzyme
)	)	O	O
is	VBZ	O	O
the	DT	O	O
key	JJ	O	O
enzyme	NN	O	O
in	IN	O	O
fumarate	JJ	O	B-SUBSTRATE
respiration	NN	O	O
induced	VBN	O	O
by	IN	O	O
anaerobic	JJ	O	O
growth	NN	O	O
of	IN	O	O
bacteria	NNS	O	O
.	.	O	O

In	IN	O	O
Helicobacter	NNP	O	O
pylori	NN	O	O
,	,	O	O
this	DT	O	O
enzyme	NN	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
constitutively	RB	O	O
expressed	VBN	O	O
under	IN	O	O
microaerobic	JJ	O	O
conditions	NNS	O	O
and	CC	O	O
is	VBZ	O	O
not	RB	O	O
essential	JJ	O	O
for	IN	O	O
its	PRP$	O	O
survival	NN	O	O
in	IN	O	O
vitro	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
FRD	NNP	O	O
in	IN	O	O
the	DT	O	O
colonization	NN	O	O
of	IN	O	O
H.	NNP	O	O
pylori	NN	O	O
was	VBD	O	O
investigated	VBN	O	O
using	VBG	O	O
a	DT	O	O
mouse	NN	O	O
model	NN	O	O
.	.	O	O

The	DT	O	O
frdA	JJ	O	O
gene	NN	O	O
coding	VBG	O	O
for	IN	O	O
subunit	NN	O	O
A	NNP	O	O
of	IN	O	O
FRD	NNP	O	O
,	,	O	O
and	CC	O	O
two	CD	O	O
control	NN	O	O
genes	NNS	O	O
,	,	O	O
copA	NN	O	B-enzyme
and	CC	O	O
copP	NN	O	B-enzyme
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
export	NN	O	O
of	IN	O	O
copper	NN	O	B-SUBSTRATE
out	IN	O	O
of	IN	O	O
H.	NNP	O	O
pylori	NN	O	O
,	,	O	O
were	VBD	O	O
inactivated	VBN	O	O
by	IN	O	O
insertion	NN	O	O
of	IN	O	O
the	DT	O	O
chloramphenicol	NN	O	O
acetyltransferase	NN	O	O
cassette	NN	O	O
into	IN	O	O
these	DT	O	O
individual	JJ	O	O
genes	NNS	O	O
.	.	O	O

The	DT	O	O
isogenic	JJ	O	O
mutants	NNS	O	O
of	IN	O	O
H.	NNP	O	O
pylori	FW	O	O
strain	NN	O	O
AH244	NNP	O	O
were	VBD	O	O
obtained	VBN	O	O
by	IN	O	O
natural	JJ	O	O
transformation	NN	O	O
.	.	O	O

Seventy-five	JJ	O	O
ICR	NNP	O	O
mice	NN	O	O
(	(	O	O
15	CD	O	O
mice/group	NN	O	O
)	)	O	O
were	VBD	O	O
orogastrically	RB	O	O
dosed	VBN	O	O
with	IN	O	O
either	CC	O	O
the	DT	O	O
wild	JJ	O	O
type	NN	O	O
H.	NNP	O	O
pylori	NN	O	O
strain	NN	O	O
AH244	NNP	O	O
,	,	O	O
its	PRP$	O	O
isogenic	JJ	O	O
mutants	NNS	O	O
,	,	O	O
or	CC	O	O
Brucella	NNP	O	O
broth	CC	O	O
(	(	O	O
negative	JJ	O	O
control	NN	O	O
)	)	O	O
.	.	O	O

Five	CD	O	O
mice	NNS	O	O
from	IN	O	O
each	DT	O	O
group	NN	O	O
were	VBD	O	O
killed	VBN	O	O
at	IN	O	O
2	CD	O	O
,	,	O	O
4	CD	O	O
and	CC	O	O
8	CD	O	O
weeks	NNS	O	O
post-inoculation	NN	O	O
(	(	O	O
WPI	NNP	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

H.	NNP	O	O
pylori	JJ	O	O
colonization	NN	O	O
was	VBD	O	O
not	RB	O	O
detected	VBN	O	O
in	IN	O	O
mouse	NN	O	O
gastric	JJ	O	O
mucosa	NN	O	O
infected	VBN	O	O
with	IN	O	O
the	DT	O	O
frdA	NN	O	O
mutant	NN	O	O
at	IN	O	O
any	DT	O	O
time	NN	O	O
point	NN	O	O
in	IN	O	O
the	DT	O	O
study	NN	O	O
by	IN	O	O
both	DT	O	O
quantitative	JJ	O	O
culture	NN	O	O
and	CC	O	O
PCR	NNP	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
the	DT	O	O
mice	NN	O	O
inoculated	VBN	O	O
with	IN	O	O
either	DT	O	O
wild	JJ	O	O
type	NN	O	O
AH244	NNP	O	O
,	,	O	O
copA	NN	O	O
or	CC	O	O
copPH	NN	O	O
.	.	O	O

pylori	JJ	O	O
mutants	NNS	O	O
became	VBD	O	O
readily	RB	O	O
infected	VBN	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
FRD	NNP	O	O
plays	VBZ	O	O
a	DT	O	O
crucial	JJ	O	O
role	NN	O	O
in	IN	O	O
H.	NNP	O	O
pylori	NN	O	O
survival	NN	O	O
in	IN	O	O
the	DT	O	O
gastric	JJ	O	O
mucosa	NN	O	O
of	IN	O	O
mice	NN	O	O
.	.	O	O

Given	VBN	O	O
that	DT	O	O
FRD	NNP	O	O
,	,	O	O
present	NN	O	O
in	IN	O	O
all	DT	O	O
H.	NNP	O	O
pylori	NN	O	O
strains	NNS	O	O
,	,	O	O
is	VBZ	O	O
immunogenic	JJ	O	O
in	IN	O	O
H.	NNP	O	O
pylori	NN	O	O
-infected	VBD	O	O
patients	NNS	O	O
and	CC	O	O
H.	NNP	O	O
pylori	VBP	O	O
growth	NN	O	O
in	IN	O	O
vitro	NN	O	O
can	MD	O	O
be	VB	O	O
inhibited	VBN	O	O
by	IN	O	O
three	CD	O	O
anthelmintics	NNS	O	O
(	(	O	O
morantel	NN	O	O
,	,	O	O
oxantel	NN	O	O
and	CC	O	O
thiabendazole	NN	O	O
)	)	O	O
,	,	O	O
this	DT	O	O
enzyme	NN	O	O
could	MD	O	O
potentially	RB	O	O
be	VB	O	O
used	VBN	O	O
both	DT	O	O
as	IN	O	O
a	DT	O	O
novel	JJ	O	O
drug	NN	O	O
target	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
vaccines	NNS	O	O
for	IN	O	O
H.	NNP	O	O
pylori	CC	O	O
prevention	NN	O	O
and	CC	O	O
eradication	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

A	DT	O	O
series	NN	O	O
of	IN	O	O
mazindol	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
and	CC	O	O
homomazindol	NN	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
analogues	NNS	O	O
with	IN	O	O
a	DT	O	O
variety	NN	O	O
of	IN	O	O
electron-donating	JJ	O	O
and	CC	O	O
electron-withdrawing	JJ	O	O
groups	NNS	O	O
in	IN	O	O
the	DT	O	O
pendant	JJ	O	O
aryl	NN	O	O
group	NN	O	O
and	CC	O	O
the	DT	O	O
benzo	NN	O	O
ring	VBG	O	O
C	NNP	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
H	NNP	O	O
,	,	O	O
methoxy	NN	O	O
,	,	O	O
and	CC	O	O
alkyl	JJ	O	O
groups	NNS	O	O
replacing	VBG	O	O
the	DT	O	O
hydroxyl	NN	O	O
group	NN	O	O
were	VBD	O	O
synthesized	VBN	O	O
,	,	O	O
and	CC	O	O
their	PRP$	O	O
binding	NN	O	O
affinities	NNS	O	O
at	IN	O	O
the	DT	O	O
dopamine	NN	O	O
transporter	NN	O	O
(	(	O	O
DAT	NNP	O	O
)	)	O	O
on	IN	O	O
rat	NN	O	O
or	CC	O	O
guinea	NN	O	O
pig	NNS	O	O
striatal	JJ	O	O
membranes	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
.	.	O	O

Several	JJ	O	O
active	JJ	O	O
analogues	NNS	O	O
were	VBD	O	O
also	RB	O	O
evaluated	VBN	O	O
for	IN	O	O
their	PRP$	O	O
ability	NN	O	O
to	TO	O	O
block	VB	O	O
uptake	NN	O	O
of	IN	O	O
DA	NNP	O	B-SUBSTRATE
,	,	O	O
5-HT	JJ	O	B-SUBSTRATE
,	,	O	O
and	CC	O	O
NE	NNP	O	B-SUBSTRATE
and	CC	O	O
inhibit	VB	O	O
binding	NN	O	O
of	IN	O	O
[	NNP	O	O
(	(	O	O
125	CD	O	O
)	)	O	O
I	PRP	O	O
]	VBP	O	O
RTI-55	JJ	O	O
at	IN	O	O
HEK-hDAT	NNP	O	O
,	,	O	O
HEK-hSERT	NNP	O	O
,	,	O	O
and	CC	O	O
HEK-hNET	NNP	O	O
cells	NNS	O	O
.	.	O	O

Mazindane	NNP	O	O
(	(	O	O
26	CD	O	O
)	)	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
pro-drug	JJ	O	O
,	,	O	O
oxidizing	VBG	O	O
(	(	O	O
5-H	CD	O	O
--	:	O	O
>	JJ	O	O
5-OH	JJ	O	O
)	)	O	O
to	TO	O	O
mazindol	VB	O	O
on	IN	O	O
rat	NN	O	O
striatal	JJ	O	O
membranes	NNS	O	O
and	CC	O	O
HEK-hDAT	NNP	O	O
cells	NNS	O	O
.	.	O	O

The	DT	O	O
4',7,8-trichloro	JJ	O	O
analogue	NN	O	O
(	(	O	O
38	CD	O	O
)	)	O	O
of	IN	O	O
mazindol	NN	O	O
was	VBD	O	O
the	DT	O	O
most	RBS	O	O
potent	JJ	O	O
and	CC	O	O
selective	JJ	O	O
ligand	NN	O	O
for	IN	O	O
HEK-hDAT	NNP	O	O
cells	NNS	O	O
(	(	O	O
DAT	NNP	O	O
K	NNP	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
=	VBD	O	O
1.1	CD	O	O
nM	NN	O	O
;	:	O	O
SERT/DAT	NNP	O	O
=	NN	O	O
1283	CD	O	O
and	CC	O	O
NET/DAT	NNP	O	O
=	NNP	O	O
38	CD	O	O
)	)	O	O
.	.	O	O

Experimental	JJ	O	O
results	NNS	O	O
strongly	RB	O	O
favor	VBP	O	O
the	DT	O	O
cyclic	NN	O	O
or	CC	O	O
ol	JJ	O	O
tautomers	NNS	O	O
of	IN	O	O
2	CD	O	O
and	CC	O	O
3	CD	O	O
to	TO	O	O
bind	VB	O	O
more	RBR	O	O
tightly	RB	O	O
at	IN	O	O
the	DT	O	O
DAT	NNP	O	O
than	IN	O	O
the	DT	O	O
corresponding	JJ	O	O
keto	NN	O	O
tautomers	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

One	CD	O	O
type	NN	O	O
of	IN	O	O
therapy	NN	O	O
for	IN	O	O
thromboembolism	NN	O	O
is	VBZ	O	O
plasmatic	JJ	O	O
thrombolysis	NN	O	O
.	.	O	O

Several	JJ	O	O
plasminogen	NN	O	O
activators	NNS	O	O
(	(	O	O
PA	NNP	O	O
)	)	O	O
are	VBP	O	O
clinically	RB	O	O
available	JJ	O	O
,	,	O	O
including	VBG	O	O
urokinase	JJ	O	O
(	(	O	O
u-PA	JJ	O	O
)	)	O	O
,	,	O	O
tissue	NN	O	O
plasminogen	NN	O	O
activator	NN	O	O
(	(	O	O
t-PA	JJ	O	O
)	)	O	O
,	,	O	O
streptokinase	FW	O	O
(	(	O	O
SK	NNP	O	O
)	)	O	O
,	,	O	O
plasminogen-streptokinase-activator-complex	JJ	O	O
(	(	O	O
PSAC	NNP	O	O
)	)	O	O
,	,	O	O
or	CC	O	O
mutants	NNS	O	O
of	IN	O	O
t-PA	JJ	O	O
such	JJ	O	O
as	IN	O	O
reteplase	NN	O	O
(	(	O	O
RP	NNP	O	O
)	)	O	O
or	CC	O	O
tenecteplase	NN	O	O
(	(	O	O
TP	NNP	O	O
)	)	O	O
.	.	O	O

Therapeutic	JJ	O	O
plasmatic	JJ	O	O
fibrinolysis	NN	O	O
was	VBD	O	O
simulated	VBN	O	O
,	,	O	O
using	VBG	O	O
the	DT	O	O
PA	NNP	O	O
at	IN	O	O
relevant	JJ	O	O
plasma	NN	O	O
concentrations	NNS	O	O
,	,	O	O
and	CC	O	O
plasmin	NN	O	O
(	(	O	O
Pli	NNP	O	O
)	)	O	O
and	CC	O	O
PA	NNP	O	O
activities	NNS	O	O
were	VBD	O	O
determined	VBN	O	O
.	.	O	O

Normal	NNP	O	O
citrated	VBD	O	O
plasma	NN	O	O
was	VBD	O	O
supplemented	VBN	O	O
with	IN	O	O
31	CD	O	O
to	TO	O	O
1,000	CD	O	O
IU/mL	NNP	O	O
u-PA	JJ	O	O
,	,	O	O
0.31	CD	O	O
to	TO	O	O
20	CD	O	O
microg/mL	NNS	O	O
t-PA	JJ	O	O
,	,	O	O
125	CD	O	O
to	TO	O	O
4,000	CD	O	O
IU/mL	NNP	O	O
SK	NNP	O	O
,	,	O	O
12.5	CD	O	O
to	TO	O	O
400	CD	O	O
U/mL	NNP	O	O
PSAC	NNP	O	O
,	,	O	O
125	CD	O	O
to	TO	O	O
4,000	CD	O	O
U/mL	NNP	O	O
RP	NNP	O	O
,	,	O	O
or	CC	O	O
0.31	CD	O	O
to	TO	O	O
10	CD	O	O
microg/mL	NN	O	O
TP	NNP	O	O
.	.	O	O

Ten	CD	O	O
IU/mL	NNP	O	O
urokinase	NN	O	O
was	VBD	O	O
also	RB	O	O
incubated	VBN	O	O
with	IN	O	O
pooled	JJ	O	O
plasma	NN	O	O
of	IN	O	O
stroke	NN	O	O
patients	NNS	O	O
,	,	O	O
that	DT	O	O
was	VBD	O	O
previously	RB	O	O
oxidized	VBN	O	O
with	IN	O	O
the	DT	O	O
singlet	NN	O	O
oxygen	NN	O	O
(	(	O	O
1O2	CD	O	O
)	)	O	O
donor	NN	O	O
chloramine	NN	O	O
T	NNP	O	O
(	(	O	O
CT	NNP	O	O
)	)	O	O
,	,	O	O
to	TO	O	O
destroy	VB	O	O
plasmatic	JJ	O	O
PAI-1	NNP	O	O
and	CC	O	O
alpha2-antiplasmin	NN	O	O
.	.	O	O

After	IN	O	O
0	CD	O	O
to	TO	O	O
80	CD	O	O
minutes	NNS	O	O
(	(	O	O
37	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
)	)	O	O
,	,	O	O
50-microL	JJ	O	O
samples	NNS	O	O
were	VBD	O	O
withdrawn	VBN	O	O
and	CC	O	O
added	VBN	O	O
to	TO	O	O
100	CD	O	O
microL	NNS	O	O
1.5	CD	O	O
M	NNP	O	O
arginine	NN	O	O
,	,	O	O
pH	NN	O	O
8.7	CD	O	O
,	,	O	O
and	CC	O	O
oxidized	VBD	O	O
with	IN	O	O
50	CD	O	O
microL	NNS	O	O
of	IN	O	O
20	CD	O	O
mM	NNS	O	O
CT.	NNP	O	O
For	IN	O	O
determination	NN	O	O
of	IN	O	O
plasmin	NN	O	B-enzyme
activity	NN	O	O
,	,	O	O
10	CD	O	O
microL	NN	O	O
thereof	NN	O	O
was	VBD	O	O
incubated	VBN	O	O
with	IN	O	O
150	CD	O	O
microL	NNS	O	O
1.5	CD	O	O
M	NNP	O	O
arginine	NN	O	B-SUBSTRATE
,	,	O	O
pH	NN	O	O
8.7	CD	O	O
,	,	O	O
and	CC	O	O
100	CD	O	O
microL	NN	O	O
20	CD	O	O
mM	NN	O	O
CT	NNP	O	O
preoxidized	VBD	O	O
(	(	O	O
15	CD	O	O
minutes	NNS	O	O
37	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
)	)	O	O
pooled	VBD	O	O
normal	JJ	O	O
citrate	NN	O	O
buffered	VBD	O	O
EDTA-plasma	NNP	O	O
for	IN	O	O
30	CD	O	O
minutes	NNS	O	O
(	(	O	O
37	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
)	)	O	O
.	.	O	O

For	IN	O	O
determination	NN	O	O
of	IN	O	O
[	NNP	O	O
PA+Pli	NNP	O	O
]	NNP	O	O
-activity	NNP	O	O
,	,	O	O
arginine	NN	O	B-SUBSTRATE
was	VBD	O	O
added	VBN	O	O
after	IN	O	O
this	DT	O	O
incubation	NN	O	O
.	.	O	O

25-microL	JJ	O	O
6	CD	O	O
mM	JJ	O	O
Val-Leu-Lys-pNA	NNP	O	O
were	VBD	O	O
added	VBN	O	O
and	CC	O	O
deltaA/h	VBN	O	O
at	IN	O	O
room	NN	O	O
temperature	NN	O	O
(	(	O	O
RT	NNP	O	O
)	)	O	O
was	VBD	O	O
monitored	VBN	O	O
,	,	O	O
using	VBG	O	O
a	DT	O	O
microtiterplate	NN	O	O
reader	NN	O	O
.	.	O	O

[	JJ	O	O
PA+Pli	NNP	O	O
]	NNP	O	O
-Pli	NNP	O	O
=	NNP	O	O
PA	NNP	O	O
.	.	O	O

The	DT	O	O
PA	NNP	O	O
concentration	NN	O	O
required	VBN	O	O
to	TO	O	O
induce	VB	O	O
25	CD	O	O
%	NN	O	O
[	JJ	O	O
ED25	NNP	O	O
]	NN	O	O
of	IN	O	O
the	DT	O	O
maximally	RB	O	O
inducible	JJ	O	O
Pli-activity	NN	O	O
in	IN	O	O
plasma	NN	O	O
(	(	O	O
=	JJ	O	O
1	CD	O	O
U/mL	NNP	O	O
=	VBD	O	O
45	CD	O	O
mg/L	NN	O	O
=	VBD	O	O
0.53	CD	O	O
micromol/L	NNS	O	O
active	JJ	O	O
Pli	NNP	O	O
;	:	O	O
deltaA	VBZ	O	O
=	$	O	O
363	CD	O	O
+/-	JJ	O	O
8	CD	O	O
mA/h	NN	O	O
RT	NNP	O	O
)	)	O	O
after	IN	O	O
10	CD	O	O
minutes	NNS	O	O
(	(	O	O
37	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
)	)	O	O
were	VBD	O	O
320	CD	O	O
IU/mL	NNP	O	O
u-PA	JJ	O	O
,	,	O	O
8	CD	O	O
microg/mL	NN	O	O
t-PA	NN	O	O
,	,	O	O
140	CD	O	O
U/mL	NNP	O	O
PSAC	NNP	O	O
,	,	O	O
6,000	CD	O	O
IU/mL	NNP	O	O
SK	NNP	O	O
,	,	O	O
720	CD	O	O
U/mL	NNP	O	O
RP	NNP	O	O
,	,	O	O
and	CC	O	O
approximately	RB	O	O
150	CD	O	O
microg/mL	NNS	O	O
TP	NNP	O	O
.	.	O	O

The	DT	O	O
approximate	JJ	O	O
activity	NN	O	O
half-lives	NNS	O	O
of	IN	O	O
the	DT	O	O
PA	NNP	O	O
in	IN	O	O
plasma	NN	O	O
were	VBD	O	O
30	CD	O	O
minutes	NNS	O	O
for	IN	O	O
u-PA	JJ	O	O
,	,	O	O
30	CD	O	O
minutes	NNS	O	O
for	IN	O	O
t-PA	NN	O	O
,	,	O	O
greater	JJR	O	O
than	IN	O	O
80	CD	O	O
minutes	NNS	O	O
for	IN	O	O
SK	NNP	O	O
,	,	O	O
greater	JJR	O	O
than	IN	O	O
80	CD	O	O
minutes	NNS	O	O
for	IN	O	O
PSAC	NNP	O	O
,	,	O	O
50	CD	O	O
minutes	NNS	O	O
for	IN	O	O
RP	NNP	O	O
,	,	O	O
and	CC	O	O
80	CD	O	O
minutes	NNS	O	O
for	IN	O	O
TP	NNP	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
shows	NNS	O	O
--	:	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
time	NN	O	O
--	:	O	O
a	DT	O	O
combined	JJ	O	O
kinetic	NN	O	O
in	IN	O	O
vitro	JJ	O	O
simulation	NN	O	O
of	IN	O	O
the	DT	O	O
plasmatic	JJ	O	O
activity	NN	O	O
of	IN	O	O
six	CD	O	O
different	JJ	O	O
PAs	NNP	O	O
.	.	O	O

At	IN	O	O
clinically	RB	O	O
used	JJ	O	O
concentrations	NNS	O	O
,	,	O	O
RP	NNP	O	O
induces	VBZ	O	O
the	DT	O	O
highest	JJS	O	O
plasmatic	JJ	O	O
Pli	NNP	O	O
activity	NN	O	O
.	.	O	O

Due	JJ	O	O
to	TO	O	O
unselective	JJ	O	O
generation	NN	O	O
of	IN	O	O
plasmin	NN	O	O
in	IN	O	O
plasma	NN	O	O
,	,	O	O
all	DT	O	O
PA	NNP	O	O
are	VBP	O	O
of	IN	O	O
some	DT	O	O
danger	NN	O	O
in	IN	O	O
inducing	VBG	O	O
severe	JJ	O	O
hemorrhagias	NN	O	O
.	.	O	O

Clinical	JJ	O	O
thrombolysis	NN	O	O
might	MD	O	O
be	VB	O	O
improved	VBN	O	O
by	IN	O	O
usage	NN	O	O
of	IN	O	O
more	JJR	O	O
physiologic	JJ	O	O
activators	NNS	O	O
of	IN	O	O
thrombolysis	NN	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
activators	NNS	O	O
of	IN	O	O
polymorphonuclear	JJ	O	O
neutrophils	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
choroid	NN	O	O
plexus	NN	O	O
uptake	NN	O	O
of	IN	O	O
[	NNP	O	B-SUBSTRATE
(	(	O	O
3	CD	O	O
)	)	O	O
H	NNP	O	O
]	NNP	O	O
cefadroxil	NN	O	O
was	VBD	O	O
studied	VBN	O	O
in	IN	O	O
peptide	NN	O	B-enzyme
transporter	NN	O	I-enzyme
2	CD	O	O
(	(	O	O
PEPT2	NNP	O	B-enzyme
)	)	O	O
wild-type	NN	O	O
and	CC	O	O
mice	NN	O	O
as	IN	O	O
a	DT	O	O
function	NN	O	O
of	IN	O	O
temperature	NN	O	O
,	,	O	O
transport	NN	O	O
inhibitors	NNS	O	O
,	,	O	O
pH	NN	O	O
,	,	O	O
and	CC	O	O
saturability	NN	O	O
.	.	O	O

At	IN	O	O
normal	JJ	O	O
pH	NN	O	O
(	(	O	O
7.4	CD	O	O
)	)	O	O
and	CC	O	O
temperature	NN	O	O
(	(	O	O
37	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
uptake	NN	O	O
of	IN	O	O
1	CD	O	O
microM	NNS	O	O
cefadroxil	NN	O	B-SUBSTRATE
was	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
83	CD	O	O
%	NN	O	O
in	IN	O	O
PEPT2	NNP	O	B-enzyme
(	(	O	O
-/-	NNP	O	O
)	)	O	O
mice	NN	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
PEPT2	NNP	O	B-enzyme
(	(	O	O
+/+	NNP	O	O
)	)	O	O
mice	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
.	.	O	O

A	DT	O	O
further	JJ	O	O
reduction	NN	O	O
was	VBD	O	O
achieved	VBN	O	O
in	IN	O	O
animals	NNS	O	O
by	IN	O	O
reducing	VBG	O	O
the	DT	O	O
temperature	NN	O	O
to	TO	O	O
4	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
,	,	O	O
or	CC	O	O
by	IN	O	O
adding	VBG	O	O
saturating	VBG	O	O
concentrations	NNS	O	O
of	IN	O	O
unlabeled	JJ	O	O
cefadroxil	NN	O	O
or	CC	O	O
p-aminohippurate	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

Glycylsarcosine	NNP	O	O
coadministration	NN	O	O
could	MD	O	O
inhibit	VB	O	O
the	DT	O	O
uptake	NN	O	O
of	IN	O	O
cefadroxil	NN	O	B-SUBSTRATE
in	IN	O	O
PEPT2	NNP	O	B-enzyme
(	(	O	O
+/+	NNP	O	O
)	)	O	O
mice	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
but	CC	O	O
not	RB	O	O
PEPT2	NNP	O	B-enzyme
(	(	O	O
-/-	NNP	O	O
)	)	O	O
mice	NN	O	O
.	.	O	O

Although	IN	O	O
a	DT	O	O
proton-stimulated	JJ	O	O
uptake	NN	O	O
of	IN	O	O
cefadroxil	NN	O	B-SUBSTRATE
was	VBD	O	O
demonstrated	VBN	O	O
in	IN	O	O
PEPT2	NNP	O	B-enzyme
(	(	O	O
+/+	NNP	O	O
)	)	O	O
mice	NN	O	O
(	(	O	O
pH	JJ	O	O
6.5	CD	O	O
versus	NN	O	O
pH	NN	O	O
7.4	CD	O	O
;	:	O	O
p	NN	O	O
<	VBZ	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
no	DT	O	O
pH	NN	O	O
dependence	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
PEPT2	NNP	O	B-enzyme
(	(	O	O
-/-	NNP	O	O
)	)	O	O
mice	NN	O	O
.	.	O	O

Kinetic	JJ	O	O
parameters	NNS	O	O
for	IN	O	O
cefadroxil	NN	O	O
(	(	O	O
without	IN	O	O
p-aminohippurate	NN	O	O
)	)	O	O
in	IN	O	O
wild-type	JJ	O	O
mice	NNS	O	O
were	VBD	O	O
:	:	O	O
V	NNP	O	O
(	(	O	O
max	NN	O	O
)	)	O	O
=	VBZ	O	O
5.4	CD	O	O
pmol/mg/min	NN	O	O
,	,	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
=	VBZ	O	O
34	CD	O	O
microM	NN	O	O
,	,	O	O
and	CC	O	O
K	NNP	O	O
(	(	O	O
d	NN	O	O
)	)	O	O
=	VBZ	O	O
0.0069	CD	O	O
microl/mg/min	NN	O	O
;	:	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
p-aminohippurate	NN	O	O
,	,	O	O
the	DT	O	O
parameters	NNS	O	O
were	VBD	O	O
:	:	O	O
V	NNP	O	O
(	(	O	O
max	NN	O	O
)	)	O	O
=	VBZ	O	O
4.1	CD	O	O
pmol/mg/min	NN	O	O
,	,	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
=	VBZ	O	O
27	CD	O	O
microM	NN	O	O
,	,	O	O
and	CC	O	O
K	NNP	O	O
(	(	O	O
d	NN	O	O
)	)	O	O
=	VBZ	O	O
0.0064	CD	O	O
microl/mg/min	NN	O	O
.	.	O	O

In	IN	O	O
animals	NNS	O	O
,	,	O	O
the	DT	O	O
kinetic	JJ	O	O
parameters	NNS	O	O
of	IN	O	O
cefadroxil	NN	O	O
(	(	O	O
without	IN	O	O
p-aminohippurate	NN	O	O
)	)	O	O
were	VBD	O	O
:	:	O	O
V	NNP	O	O
(	(	O	O
max	NN	O	O
)	)	O	O
=	VBZ	O	O
2.7	CD	O	O
pmol/mg/min	NN	O	O
,	,	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
=	VBZ	O	O
110	CD	O	O
microM	NN	O	O
,	,	O	O
and	CC	O	O
K	NNP	O	O
(	(	O	O
d	NN	O	O
)	)	O	O
=	VBZ	O	O
0.0084	CD	O	O
microl/mg/min	NN	O	O
;	:	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
p-aminohippurate	NN	O	O
,	,	O	O
only	RB	O	O
a	DT	O	O
K	NNP	O	O
(	(	O	O
d	NN	O	O
)	)	O	O
=	VBZ	O	O
0.010	CD	O	O
microl/mg/min	NN	O	O
was	VBD	O	O
observed	VBN	O	O
.	.	O	O

Based	VBN	O	O
on	IN	O	O
kinetic	JJ	O	O
and	CC	O	O
inhibitor	NN	O	O
analyses	NNS	O	O
,	,	O	O
it	PRP	O	O
was	VBD	O	O
determined	VBN	O	O
that	IN	O	O
(	(	O	O
under	IN	O	O
linear	JJ	O	O
conditions	NNS	O	O
)	)	O	O
,	,	O	O
80	CD	O	O
to	TO	O	O
85	CD	O	O
%	NN	O	O
of	IN	O	O
cefadroxil	NN	O	O
's	POS	O	O
uptake	NN	O	O
in	IN	O	O
choroid	JJ	O	O
plexus	NN	O	O
is	VBZ	O	O
mediated	VBN	O	O
by	IN	O	O
PEPT2	NNP	O	O
,	,	O	O
10	CD	O	O
to	TO	O	O
15	CD	O	O
%	NN	O	O
by	IN	O	O
organic	JJ	O	O
anion	NN	O	O
transporter	NN	O	O
(	(	O	O
s	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
5	CD	O	O
%	NN	O	O
by	IN	O	O
nonspecific	JJ	O	O
mechanisms	NNS	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
demonstrate	VBP	O	O
that	IN	O	O
PEPT2	NNP	O	B-enzyme
is	VBZ	O	O
the	DT	O	O
primary	JJ	O	O
transporter	NN	O	O
responsible	JJ	O	O
for	IN	O	O
cefadroxil	JJ	O	B-SUBSTRATE
uptake	NN	O	O
in	IN	O	O
the	DT	O	O
choroid	NN	O	O
plexus	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
the	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
a	DT	O	O
role	NN	O	O
for	IN	O	O
PEPT2	NNP	O	O
in	IN	O	O
the	DT	O	O
clearance	NN	O	O
of	IN	O	O
peptidomimetics	NNS	O	O
from	IN	O	O
cerebrospinal	JJ	O	O
fluid	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Quinone	NNP	O	O
oxidoreductase	NN	O	O
2	CD	O	O
(	(	O	O
QR2	NNP	O	O
)	)	O	O
purified	VBD	O	O
from	IN	O	O
human	JJ	O	O
red	JJ	O	O
blood	NN	O	O
cells	NNS	O	O
was	VBD	O	O
recently	RB	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
potential	JJ	O	O
target	NN	O	O
of	IN	O	O
the	DT	O	O
quinoline	JJ	O	O
antimalarial	JJ	O	O
compounds	NNS	O	O
[	VBP	O	O
Graves	VBZ	O	O
et	FW	O	O
al.	NN	O	O
,	,	O	O
(	(	O	O
2002	CD	O	O
)	)	O	O
Mol	NNP	O	O
.	.	O	O

Pharmacol	NNP	O	O
.	.	O	O

62	CD	O	O
,	,	O	O
1364	CD	O	O
]	NN	O	O
.	.	O	O

QR2	NNP	O	B-enzyme
catalyzes	VBZ	O	O
the	DT	O	O
two-electron	JJ	O	O
reduction	NN	O	O
of	IN	O	O
menadione	NN	O	B-SUBSTRATE
via	IN	O	O
the	DT	O	O
oxidation	NN	O	O
of	IN	O	O
N-alkylated	JJ	O	B-SUBSTRATE
or	CC	O	O
N-ribosylated	JJ	O	B-SUBSTRATE
nicotinamides	NNS	O	I-SUBSTRATE
.	.	O	O

To	TO	O	O
investigate	VB	O	O
the	DT	O	O
mechanism	NN	O	O
and	CC	O	O
consequences	NNS	O	O
of	IN	O	O
inhibition	NN	O	O
of	IN	O	O
QR2	NNP	O	O
by	IN	O	O
the	DT	O	O
quinolines	NNS	O	O
further	RB	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
used	VBN	O	O
steady-state	JJ	O	O
and	CC	O	O
transient-state	JJ	O	O
kinetics	NNS	O	O
to	TO	O	O
define	VB	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
QR2	NNP	O	O
.	.	O	O

Importantly	RB	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
QR2	NNP	O	O
when	WRB	O	O
isolated	VBN	O	O
from	IN	O	O
an	DT	O	O
overproducing	VBG	O	O
strain	NN	O	O
of	IN	O	O
E.	NNP	O	O
coli	NNS	O	O
is	VBZ	O	O
kinetically	RB	O	O
equivalent	JJ	O	O
to	TO	O	O
the	DT	O	O
enzyme	NN	O	O
from	IN	O	O
the	DT	O	O
native	JJ	O	O
human	JJ	O	O
red	JJ	O	O
blood	NN	O	O
cell	NN	O	O
source	NN	O	O
.	.	O	O

We	PRP	O	O
observe	VBP	O	O
ping-pong	JJ	O	O
kinetics	NNS	O	O
consistent	JJ	O	O
with	IN	O	O
one	CD	O	O
substrate/inhibitor	NN	O	O
binding	VBG	O	O
site	NN	O	O
that	WDT	O	O
shows	VBZ	O	O
selectivity	NN	O	O
for	IN	O	O
the	DT	O	O
oxidation	NN	O	O
state	NN	O	O
of	IN	O	O
the	DT	O	O
FAD	NNP	O	O
cofactor	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
selective	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
the	DT	O	O
liver	NN	O	O
versus	NN	O	O
red	VBD	O	O
blood	NN	O	O
cell	NN	O	O
forms	NNS	O	O
of	IN	O	O
malaria	NN	O	O
may	MD	O	O
be	VB	O	O
possible	JJ	O	O
.	.	O	O

The	DT	O	O
reductant	JJ	O	O
N-methyldihydronicotinamide	NNP	O	O
and	CC	O	O
the	DT	O	O
inhibitor	NN	O	O
primaquine	NN	O	O
bind	NN	O	O
exclusively	RB	O	O
to	TO	O	O
the	DT	O	O
oxidized	VBN	O	O
enzyme	NN	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
the	DT	O	O
inhibitors	NNS	O	O
quinacrine	VBP	O	O
and	CC	O	O
chloroquine	VBP	O	O
bind	NN	O	O
exclusively	RB	O	O
to	TO	O	O
the	DT	O	O
reduced	VBN	O	O
enzyme	NN	O	O
.	.	O	O

The	DT	O	O
quinone	NN	O	O
substrate	NN	O	O
menadione	NN	O	O
,	,	O	O
on	IN	O	O
the	DT	O	O
other	JJ	O	O
hand	NN	O	O
,	,	O	O
binds	VBZ	O	O
nonspecifically	RB	O	O
to	TO	O	O
both	DT	O	O
forms	NNS	O	O
of	IN	O	O
the	DT	O	O
enzyme	NN	O	O
.	.	O	O

Single-turnover	JJ	O	O
kinetics	NNS	O	O
of	IN	O	O
the	DT	O	O
reductive	JJ	O	O
half-reaction	NN	O	O
are	VBP	O	O
chemically	RB	O	O
and	CC	O	O
kinetically	RB	O	O
competent	JJ	O	O
and	CC	O	O
confirm	VBP	O	O
the	DT	O	O
inhibitor	NN	O	O
selectivity	NN	O	O
seen	VBN	O	O
in	IN	O	O
the	DT	O	O
steady-state	JJ	O	O
experiments	NNS	O	O
.	.	O	O

Our	PRP$	O	O
studies	NNS	O	O
shed	VBN	O	O
light	NN	O	O
on	IN	O	O
the	DT	O	O
possible	JJ	O	O
in	IN	O	O
vivo	JJ	O	O
potency	NN	O	O
of	IN	O	O
the	DT	O	O
quinolines	NNS	O	O
and	CC	O	O
provide	VB	O	O
a	DT	O	O
foundation	NN	O	O
for	IN	O	O
future	JJ	O	O
studies	NNS	O	O
aimed	VBN	O	O
at	IN	O	O
creating	VBG	O	O
more	JJR	O	O
potent	JJ	O	O
QR2	NNP	O	O
inhibitors	NNS	O	O
and	CC	O	O
at	IN	O	O
understanding	VBG	O	O
the	DT	O	O
physiological	JJ	O	O
significance	NN	O	O
of	IN	O	O
QR2	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Monocarboxylate	NNP	O	B-enzyme
transporters	NNS	O	I-enzyme
(	(	O	O
MCTs	NNP	O	B-enzyme
)	)	O	O
are	VBP	O	O
proton-linked	JJ	O	O
membrane	NN	O	O
carriers	NNS	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
transport	NN	O	O
of	IN	O	O
monocarboxylates	NNS	O	B-SUBSTRATE
such	JJ	O	O
as	IN	O	O
lactate	NN	O	B-SUBSTRATE
,	,	O	O
pyruvate	NN	O	B-SUBSTRATE
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
ketone	NN	O	B-SUBSTRATE
bodies	NNS	O	O
.	.	O	O

They	PRP	O	O
belong	VBP	O	O
to	TO	O	O
a	DT	O	O
larger	JJR	O	O
family	NN	O	O
of	IN	O	O
transporters	NNS	O	O
composed	VBN	O	O
of	IN	O	O
14	CD	O	O
members	NNS	O	O
in	IN	O	O
mammals	NNS	O	O
based	VBN	O	O
on	IN	O	O
sequence	NN	O	O
homologies	NNS	O	O
.	.	O	O

MCTs	NNP	O	O
are	VBP	O	O
found	VBN	O	O
in	IN	O	O
various	JJ	O	O
tissues	NNS	O	O
including	VBG	O	O
the	DT	O	O
brain	NN	O	O
where	WRB	O	O
three	CD	O	O
isoforms	NNS	O	O
,	,	O	O
MCT1	NNP	O	O
,	,	O	O
MCT2	NNP	O	O
and	CC	O	O
MCT4	NNP	O	O
,	,	O	O
have	VBP	O	O
been	VBN	O	O
described	VBN	O	O
.	.	O	O

Each	DT	O	O
of	IN	O	O
these	DT	O	O
isoforms	NNS	O	O
exhibits	VBP	O	O
a	DT	O	O
distinct	JJ	O	O
regional	JJ	O	O
and	CC	O	O
cellular	JJ	O	O
distribution	NN	O	O
in	IN	O	O
rodent	NN	O	O
brain	NN	O	O
.	.	O	O

At	IN	O	O
the	DT	O	O
cellular	JJ	O	O
level	NN	O	O
,	,	O	O
MCT1	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
by	IN	O	O
endothelial	JJ	O	O
cells	NNS	O	O
of	IN	O	O
microvessels	NNS	O	O
,	,	O	O
by	IN	O	O
ependymocytes	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
by	IN	O	O
astrocytes	NNS	O	O
.	.	O	O

MCT4	NNP	O	O
expression	NN	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
specific	JJ	O	O
for	IN	O	O
astrocytes	NNS	O	O
.	.	O	O

By	IN	O	O
contrast	NN	O	O
,	,	O	O
the	DT	O	O
predominant	JJ	O	O
neuronal	JJ	O	O
monocarboxylate	NN	O	O
transporter	NN	O	O
is	VBZ	O	O
MCT2	NNP	O	O
.	.	O	O

Interestingly	RB	O	O
,	,	O	O
part	NN	O	O
of	IN	O	O
MCT2	NNP	O	B-enzyme
immunoreactivity	NN	O	O
is	VBZ	O	O
located	VBN	O	O
at	IN	O	O
postsynaptic	JJ	O	O
sites	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
a	DT	O	O
particular	JJ	O	O
role	NN	O	O
of	IN	O	O
monocarboxylates	NNS	O	B-SUBSTRATE
and	CC	O	O
their	PRP$	O	O
transporters	NNS	O	O
in	IN	O	O
synaptic	JJ	O	O
transmission	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
to	TO	O	O
variation	NN	O	O
in	IN	O	O
expression	NN	O	O
during	IN	O	O
development	NN	O	O
and	CC	O	O
upon	IN	O	O
nutritional	JJ	O	O
modifications	NNS	O	O
,	,	O	O
new	JJ	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
MCT	NNP	O	O
expression	NN	O	O
is	VBZ	O	O
regulated	VBN	O	O
at	IN	O	O
the	DT	O	O
translational	JJ	O	O
level	NN	O	O
by	IN	O	O
neurotransmitters	NNS	O	O
.	.	O	O

Understanding	VBG	O	O
how	WRB	O	O
transport	NN	O	O
of	IN	O	O
monocarboxylates	NNS	O	O
is	VBZ	O	O
regulated	VBN	O	O
could	MD	O	O
be	VB	O	O
of	IN	O	O
particular	JJ	O	O
importance	NN	O	O
not	RB	O	O
only	RB	O	O
for	IN	O	O
neuroenergetics	NNS	O	O
but	CC	O	O
also	RB	O	O
for	IN	O	O
areas	NNS	O	O
such	JJ	O	O
as	IN	O	O
functional	JJ	O	O
brain	NN	O	O
imaging	NN	O	O
,	,	O	O
regulation	NN	O	O
of	IN	O	O
food	NN	O	O
intake	NN	O	O
and	CC	O	O
glucose	JJ	O	O
homeostasis	NN	O	O
,	,	O	O
or	CC	O	O
for	IN	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
disorders	NNS	O	O
such	JJ	O	O
as	IN	O	O
ischaemia	NN	O	O
and	CC	O	O
neurodegenerative	JJ	O	O
diseases	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
Omega	NNP	O	O
class	NN	O	O
of	IN	O	O
cytosolic	JJ	O	O
glutathione	NN	O	O
transferases	NNS	O	O
was	VBD	O	O
initially	RB	O	O
recognized	VBN	O	O
by	IN	O	O
bioinformatic	JJ	O	O
analysis	NN	O	O
of	IN	O	O
human	JJ	O	O
sequence	NN	O	O
databases	NNS	O	O
,	,	O	O
and	CC	O	O
orthologous	JJ	O	O
sequences	NNS	O	O
were	VBD	O	O
subsequently	RB	O	O
discovered	VBN	O	O
in	IN	O	O
mouse	NN	O	O
,	,	O	O
rat	NN	O	O
,	,	O	O
pig	NN	O	O
,	,	O	O
Caenorhabditis	NNP	O	O
elegans	VBZ	O	O
,	,	O	O
Schistosoma	NNP	O	O
mansoni	NN	O	O
,	,	O	O
and	CC	O	O
Drosophila	NNP	O	O
melanogaster	NN	O	O
.	.	O	O

In	IN	O	O
humans	NNS	O	O
and	CC	O	O
mice	NNS	O	O
,	,	O	O
two	CD	O	O
GSTO	NNP	O	O
genes	NNS	O	O
have	VBP	O	O
been	VBN	O	O
recognized	VBN	O	O
and	CC	O	O
their	PRP$	O	O
genetic	JJ	O	O
structures	NNS	O	O
and	CC	O	O
expression	NN	O	O
patterns	NNS	O	O
identified	VBN	O	O
.	.	O	O

In	IN	O	O
both	DT	O	O
species	NNS	O	O
,	,	O	O
GSTO1	NNP	O	O
mRNA	NN	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
liver	NN	O	O
and	CC	O	O
heart	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
a	DT	O	O
range	NN	O	O
of	IN	O	O
other	JJ	O	O
tissues	NNS	O	O
.	.	O	O

GSTO2	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
predominantly	RB	O	O
in	IN	O	O
the	DT	O	O
testis	NN	O	O
,	,	O	O
although	IN	O	O
moderate	JJ	O	O
levels	NNS	O	O
of	IN	O	O
expression	NN	O	O
are	VBP	O	O
seen	VBN	O	O
in	IN	O	O
other	JJ	O	O
tissues	NNS	O	O
.	.	O	O

Extensive	JJ	O	O
immunohistochemistry	NN	O	O
of	IN	O	O
rat	NN	O	O
and	CC	O	O
human	JJ	O	O
tissue	NN	O	O
sections	NNS	O	O
has	VBZ	O	O
demonstrated	VBN	O	O
cellular	JJ	O	O
and	CC	O	O
subcellular	JJ	O	O
specificity	NN	O	O
in	IN	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
GSTO1-1	NNP	O	O
.	.	O	O

The	DT	O	O
crystal	JJ	O	O
structure	NN	O	O
of	IN	O	O
recombinant	JJ	O	O
human	JJ	O	O
GSTO1-1	NNP	O	O
has	VBZ	O	O
been	VBN	O	O
determined	VBN	O	O
,	,	O	O
and	CC	O	O
it	PRP	O	O
adopts	VBZ	O	O
the	DT	O	O
canonical	JJ	O	O
GST	NNP	O	O
fold	NN	O	O
.	.	O	O

A	DT	O	O
cysteine	NN	O	O
residue	NN	O	O
in	IN	O	O
place	NN	O	O
of	IN	O	O
the	DT	O	O
catalytic	JJ	O	O
tyrosine	NN	O	O
or	CC	O	O
serine	NN	O	O
residues	NNS	O	O
found	VBN	O	O
in	IN	O	O
other	JJ	O	O
GSTs	NNP	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
form	VB	O	O
a	DT	O	O
mixed	JJ	O	O
disulfide	NN	O	O
with	IN	O	O
glutathione	NN	O	O
.	.	O	O

Omega	NNP	O	B-enzyme
class	NN	O	I-enzyme
GSTs	NNP	O	O
have	VBP	O	O
dehydroascorbate	JJ	O	O
reductase	NN	O	O
and	CC	O	O
thioltransferase	NN	O	O
activities	NNS	O	O
and	CC	O	O
also	RB	O	O
catalyze	VBP	O	O
the	DT	O	O
reduction	NN	O	O
of	IN	O	O
monomethylarsonate	NN	O	B-SUBSTRATE
,	,	O	O
an	DT	O	O
intermediate	NN	O	O
in	IN	O	O
the	DT	O	O
pathway	NN	O	O
of	IN	O	O
arsenic	JJ	O	O
biotransformation	NN	O	O
.	.	O	O

Other	JJ	O	O
diverse	JJ	O	O
actions	NNS	O	O
of	IN	O	O
human	JJ	O	O
GSTO1-1	NNP	O	O
include	NN	O	O
modulation	NN	O	O
of	IN	O	O
ryanodine	NN	O	O
receptors	NNS	O	O
and	CC	O	O
interaction	NN	O	O
with	IN	O	O
cytokine	JJ	O	O
release	NN	O	O
inhibitory	NN	O	O
drugs	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
GSTO1	NNP	O	O
has	VBZ	O	O
been	VBN	O	O
linked	VBN	O	O
to	TO	O	O
the	DT	O	O
age	NN	O	O
at	IN	O	O
onset	NN	O	O
of	IN	O	O
both	DT	O	O
Alzheimer	NNP	O	O
's	POS	O	O
and	CC	O	O
Parkinson	NNP	O	O
's	POS	O	O
diseases	NNS	O	O
.	.	O	O

Several	JJ	O	O
polymorphisms	NNS	O	O
have	VBP	O	O
been	VBN	O	O
identified	VBN	O	O
in	IN	O	O
the	DT	O	O
coding	NN	O	O
regions	NNS	O	O
of	IN	O	O
the	DT	O	O
human	JJ	O	O
GSTO1	NNP	O	O
and	CC	O	O
GSTO2	NNP	O	O
genes	NNS	O	O
.	.	O	O

Our	PRP$	O	O
laboratory	NN	O	O
has	VBZ	O	O
expressed	VBN	O	O
recombinant	JJ	O	O
human	JJ	O	O
GSTO1-1	NNP	O	O
and	CC	O	O
GSTO2-2	NNP	O	O
proteins	NNS	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
polymorphic	JJ	O	O
variants	NNS	O	O
.	.	O	O

The	DT	O	O
expression	NN	O	O
and	CC	O	O
purification	NN	O	O
of	IN	O	O
these	DT	O	O
proteins	NNS	O	O
and	CC	O	O
determination	NN	O	O
of	IN	O	O
their	PRP$	O	O
enzymatic	JJ	O	O
activity	NN	O	O
is	VBZ	O	O
described	VBN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Acetohydroxyacid	NNP	O	O
synthase	NN	O	O
(	(	O	O
AHAS	NNP	O	O
)	)	O	O
inhibitors	NNS	O	O
interfere	RB	O	O
with	IN	O	O
branched-chain	JJ	O	O
amino	NN	O	O
acid	NN	O	O
biosynthesis	NN	O	O
by	IN	O	O
inhibiting	VBG	O	O
AHAS	NNP	O	O
.	.	O	O

Glyphosate	NNP	O	O
affects	VBZ	O	O
aromatic	JJ	O	O
amino	NN	O	O
acid	JJ	O	O
biosynthesis	NN	O	O
by	IN	O	O
inhibiting	VBG	O	O
5-enolpyruvylshikimate-3-phosphate	JJ	O	O
synthase	NN	O	O
(	(	O	O
EPSPS	NNP	O	O
)	)	O	O
.	.	O	O

Glufosinate	NNP	O	O
inhibits	NNS	O	O
glutamine	VBP	O	B-enzyme
synthetase	NN	O	I-enzyme
and	CC	O	O
blocks	NNS	O	O
biosynthesis	NN	O	O
of	IN	O	O
glutamine	NN	O	B-PRODUCT-OF
.	.	O	O

AHAS	NNP	O	O
gene	NN	O	O
variants	NNS	O	O
that	WDT	O	O
confer	VBP	O	O
tolerance	NN	O	O
to	TO	O	O
AHAS	NNP	O	O
inhibitors	NNS	O	O
have	VBP	O	O
been	VBN	O	O
discovered	VBN	O	O
in	IN	O	O
plants	NNS	O	O
through	IN	O	O
selection	NN	O	O
or	CC	O	O
mutagenesis	NN	O	O
.	.	O	O

Imidazolinone-tolerant	JJ	O	O
crops	NNS	O	O
have	VBP	O	O
been	VBN	O	O
commercialized	VBN	O	O
based	VBN	O	O
on	IN	O	O
these	DT	O	O
AHAS	NNP	O	O
gene	NN	O	O
variants	NNS	O	O
.	.	O	O

A	DT	O	O
modified	JJ	O	O
maize	NN	O	O
EPSPS	NNP	O	O
gene	NN	O	O
and	CC	O	O
CP4-EPSPS	JJ	O	O
gene	NN	O	O
from	IN	O	O
Agrobacterium	NNP	O	O
sp	NN	O	O
.	.	O	O

have	VBP	O	O
been	VBN	O	O
used	VBN	O	O
to	TO	O	O
transform	VB	O	O
plants	NNS	O	O
for	IN	O	O
target-based	JJ	O	O
tolerance	NN	O	O
to	TO	O	O
glyphosate	VB	O	O
.	.	O	O

A	DT	O	O
gox	JJ	O	O
gene	NN	O	O
isolated	VBD	O	O
from	IN	O	O
Ochrobactrum	NNP	O	O
anthropi	NN	O	O
has	VBZ	O	O
also	RB	O	O
been	VBN	O	O
employed	VBN	O	O
to	TO	O	O
encode	VB	O	O
glyphosate	JJ	O	O
oxidoreductase	NN	O	O
to	TO	O	O
detoxify	VB	O	O
glyphosate	NN	O	O
in	IN	O	O
plants	NNS	O	O
.	.	O	O

Glyphosate-tolerant	JJ	O	O
crops	NNS	O	O
with	IN	O	O
EPSPS	NNP	O	O
transgene	VBP	O	O
alone	RB	O	O
or	CC	O	O
both	DT	O	O
EPSPS	NNP	O	O
and	CC	O	O
gox	NN	O	O
transgenes	NNS	O	O
have	VBP	O	O
been	VBN	O	O
commercialized	VBN	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
bar	NN	O	O
and	CC	O	O
pat	NN	O	O
genes	NNS	O	O
isolated	VBN	O	O
from	IN	O	O
Streptomyces	NNP	O	O
hygroscopicus	NN	O	O
and	CC	O	O
S.	NNP	O	O
viridochromogenes	NNS	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
have	VBP	O	O
been	VBN	O	O
inserted	VBN	O	O
into	IN	O	O
plants	NNS	O	O
to	TO	O	O
encode	VB	O	O
phosphinothricin	JJ	O	O
N-acetyltransferase	NNP	O	O
to	TO	O	O
detoxify	VB	O	O
glufosinate	NN	O	O
.	.	O	O

Glufosinate-tolerant	JJ	O	O
crops	NNS	O	O
have	VBP	O	O
been	VBN	O	O
commercialized	VBN	O	O
using	VBG	O	O
one	CD	O	O
of	IN	O	O
these	DT	O	O
two	CD	O	O
transgenes	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

OBJECTIVE	NN	O	O
:	:	O	O
To	TO	O	O
compare	VB	O	O
the	DT	O	O
cyclooxygenase	NN	O	O
(	(	O	O
COX	NNP	O	O
)	)	O	O
activity	NN	O	O
and	CC	O	O
anti-inflammatory	JJ	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
nonsteroidal	JJ	O	O
anti-inflammatory	JJ	O	O
drugs	NNS	O	O
(	(	O	O
NSAIDs	NNP	O	O
)	)	O	O
ketorolac	FW	O	O
tromethamine	NN	O	O
(	(	O	O
ketorolac	NN	O	O
)	)	O	O
and	CC	O	O
bromfenac	JJ	O	O
sodium	NN	O	O
(	(	O	O
bromfenac	NN	O	O
)	)	O	O
.	.	O	O

METHODS	NN	O	O
:	:	O	O
Cyclooxygenase	NNP	O	B-enzyme
activity	NN	O	O
and	CC	O	O
selectivity	NN	O	O
was	VBD	O	O
determined	VBN	O	O
in	IN	O	O
vitro	NN	O	O
by	IN	O	O
measuring	VBG	O	O
prostaglandin	NN	O	B-PRODUCT-OF
E	NNP	O	I-PRODUCT-OF
(	(	O	I-PRODUCT-OF
2	CD	O	I-PRODUCT-OF
)	)	O	I-PRODUCT-OF
(	(	O	O
PGE	NNP	O	B-PRODUCT-OF
(	(	O	O
2	CD	O	O
)	)	O	O
)	)	O	I-PRODUCT-OF
production	NN	O	O
following	VBG	O	O
incubation	NN	O	O
of	IN	O	O
varying	VBG	O	O
concentrations	NNS	O	O
of	IN	O	O
NSAID	NNP	O	O
with	IN	O	O
human	JJ	O	O
recombinant	JJ	O	O
COX-1	NNP	O	O
or	CC	O	O
COX-2	NNP	O	O
and	CC	O	O
arachidonic	JJ	O	O
acid	NN	O	O
.	.	O	O

Anti-inflammatory	JJ	O	O
effects	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
in	IN	O	O
a	DT	O	O
rabbit	NN	O	O
model	NN	O	O
in	IN	O	O
which	WDT	O	O
an	DT	O	O
ocular	JJ	O	O
inflammatory	NN	O	O
response	NN	O	O
was	VBD	O	O
induced	VBN	O	O
by	IN	O	O
intravenous	JJ	O	O
injection	NN	O	O
of	IN	O	O
10	CD	O	O
microg/kg	NNS	O	O
lipopolysaccharide	RB	O	O
(	(	O	O
LPS	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
study	NN	O	O
animals	NNS	O	O
,	,	O	O
one	CD	O	O
eye	NN	O	O
was	VBD	O	O
treated	VBN	O	O
with	IN	O	O
50	CD	O	O
microL	NNS	O	O
(	(	O	O
+/-	JJ	O	O
)	)	O	O
ketorolac	VB	O	O
0.4	CD	O	O
%	NN	O	O
(	(	O	O
Acular	NNP	O	O
LS	NNP	O	O
)	)	O	O
or	CC	O	O
bromfenac	$	O	O
0.09	CD	O	O
%	NN	O	O
(	(	O	O
Xibrom	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
other	JJ	O	O
eye	NN	O	O
with	IN	O	O
50	CD	O	O
microL	NNS	O	O
buffered	VBN	O	O
saline	NN	O	O
.	.	O	O

In	IN	O	O
control	NN	O	O
animals	NNS	O	O
,	,	O	O
both	DT	O	O
eyes	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
vehicle	NN	O	O
.	.	O	O

All	DT	O	O
animals	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
twice	RB	O	O
:	:	O	O
2	CD	O	O
hours	NNS	O	O
and	CC	O	O
1	CD	O	O
hour	NN	O	O
before	IN	O	O
LPS	NNP	O	O
.	.	O	O

MAIN	NNP	O	O
OUTCOME	NNP	O	O
MEASURES	NNP	O	O
:	:	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
production	NN	O	O
in	IN	O	O
vitro	NN	O	O
,	,	O	O
measured	VBN	O	O
by	IN	O	O
enzyme	JJ	O	O
immunoassay	NN	O	O
;	:	O	O
fluorescein	JJ	O	O
isothiocyanate	NN	O	O
(	(	O	O
FITC	NNP	O	O
)	)	O	O
-dextran	VBD	O	O
leakage	NN	O	O
into	IN	O	O
the	DT	O	O
anterior	JJ	O	O
chamber	NN	O	O
,	,	O	O
measured	VBN	O	O
by	IN	O	O
fluorophotometry	NN	O	O
;	:	O	O
aqueous	JJ	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
levels	NNS	O	O
in	IN	O	O
vivo	NN	O	O
,	,	O	O
measured	VBN	O	O
by	IN	O	O
ELISA	NNP	O	O
immunoassay	NN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
Ketorolac	NNP	O	O
was	VBD	O	O
six	CD	O	O
times	NNS	O	O
more	RBR	O	O
active	JJ	O	O
against	IN	O	O
COX-1	NNP	O	O
(	(	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
=	VBD	O	O
0.02	CD	O	O
microM	NN	O	O
)	)	O	O
than	IN	O	O
COX-2	NNP	O	O
(	(	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
=	VBD	O	O
0.12	CD	O	O
microM	NNS	O	O
)	)	O	O
while	IN	O	O
bromfenac	NN	O	O
was	VBD	O	O
approximately	RB	O	O
32	CD	O	O
times	NNS	O	O
more	RBR	O	O
active	JJ	O	O
against	IN	O	O
COX-2	NNP	O	O
(	(	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
=	VBD	O	O
0.0066	CD	O	O
microM	NN	O	O
)	)	O	O
than	IN	O	O
COX-1	NNP	O	O
(	(	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
=	VBD	O	O
0.210	CD	O	O
microM	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
animal	JJ	O	O
model	NN	O	O
,	,	O	O
both	DT	O	O
drugs	NNS	O	O
resulted	VBD	O	O
in	IN	O	O
nearly	RB	O	O
complete	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
FITC-dextran	NNP	O	O
leakage	NN	O	O
and	CC	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
production	NN	O	O
in	IN	O	O
the	DT	O	O
anterior	JJ	O	O
chamber	NN	O	O
of	IN	O	O
treated	JJ	O	O
eyes	NNS	O	O
.	.	O	O

There	EX	O	O
was	VBD	O	O
also	RB	O	O
a	DT	O	O
79	CD	O	O
%	NN	O	O
inhibition	NN	O	O
(	(	O	O
p	JJ	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
of	IN	O	O
FITC-dextran	NNP	O	O
leakage	NN	O	O
in	IN	O	O
the	DT	O	O
contralateral	JJ	O	O
eyes	NNS	O	O
of	IN	O	O
bromfenac-treated	JJ	O	O
rabbits	NNS	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
22.5	CD	O	O
%	NN	O	O
inhibition	NN	O	O
(	(	O	O
not	RB	O	O
statistically	RB	O	O
significant	JJ	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
contralateral	JJ	O	O
eyes	NNS	O	O
of	IN	O	O
ketorolac-treated	JJ	O	O
rabbits	NNS	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
Ketorolac	NNP	O	O
is	VBZ	O	O
relatively	RB	O	O
COX-1	JJ	O	O
selective	NN	O	O
while	IN	O	O
bromfenac	NN	O	O
is	VBZ	O	O
potently	RB	O	O
selective	JJ	O	O
for	IN	O	O
COX-2	NNP	O	O
over	IN	O	O
COX-1	NNP	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
animal	JJ	O	O
model	NN	O	O
,	,	O	O
both	DT	O	O
ketorolac	VBP	O	O
0.4	CD	O	O
%	NN	O	O
and	CC	O	O
bromfenac	VB	O	O
0.09	CD	O	O
%	NN	O	O
demonstrated	VBD	O	O
maximal	JJ	O	O
anti-inflammatory	JJ	O	O
activity	NN	O	O
in	IN	O	O
treated	JJ	O	O
eyes	NNS	O	O
.	.	O	O

Only	RB	O	O
bromfenac	RB	O	O
0.09	CD	O	O
%	NN	O	O
had	VBD	O	O
a	DT	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
contralateral	JJ	O	O
eye	NN	O	O
,	,	O	O
suggesting	VBG	O	O
possible	JJ	O	O
systemic	JJ	O	O
absorption	NN	O	O
of	IN	O	O
this	DT	O	O
drug	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Licofelone	NNP	O	O
,	,	O	O
a	DT	O	O
dual	JJ	O	O
anti-inflammatory	JJ	O	O
drug	NN	O	O
that	IN	O	O
inhibits	VBZ	O	O
5-lipoxygenase	NN	O	O
(	(	O	O
LOX	NNP	O	O
)	)	O	O
and	CC	O	O
cyclooxygenase	NN	O	O
(	(	O	O
COX	NNP	O	O
)	)	O	O
enzymes	NNS	O	O
,	,	O	O
may	MD	O	O
have	VB	O	O
a	DT	O	O
better	JJR	O	O
cardiovascular	NN	O	O
profile	NN	O	O
that	IN	O	O
cycloxygenase-2	JJ	O	O
inhibitors	NNS	O	O
due	JJ	O	O
to	TO	O	O
cycloxygenase-1	JJ	O	O
blockade-mediated	JJ	O	O
antithrombotic	JJ	O	O
effect	NN	O	O
and	CC	O	O
a	DT	O	O
better	JJR	O	O
gastrointestinal	JJ	O	O
tolerability	NN	O	O
.	.	O	O

We	PRP	O	O
examined	VBD	O	O
the	DT	O	O
anti-inflammatory	JJ	O	O
effect	NN	O	O
of	IN	O	O
licofelone	NN	O	O
on	IN	O	O
atherosclerotic	JJ	O	O
lesions	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
in	IN	O	O
isolated	JJ	O	O
neutrophils	NNS	O	O
from	IN	O	O
whole	JJ	O	O
blood	NN	O	O
of	IN	O	O
rabbits	NNS	O	O
compared	VBN	O	O
with	IN	O	O
a	DT	O	O
selective	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
COX-2	NNP	O	O
,	,	O	O
rofecoxib	NN	O	O
.	.	O	O

We	PRP	O	O
also	RB	O	O
assessed	VBD	O	O
the	DT	O	O
antithrombotic	JJ	O	O
effect	NN	O	O
of	IN	O	O
licofelone	NN	O	O
in	IN	O	O
rabbit	NN	O	O
platelet-rich	JJ	O	O
plasma	NN	O	O
.	.	O	O

For	IN	O	O
this	DT	O	O
purpose	NN	O	O
,	,	O	O
30	CD	O	O
rabbits	NNS	O	O
underwent	JJ	O	O
injury	NN	O	O
of	IN	O	O
femoral	JJ	O	O
arteries	NNS	O	O
,	,	O	O
and	CC	O	O
they	PRP	O	O
were	VBD	O	O
randomized	VBN	O	O
to	TO	O	O
receive	VB	O	O
10	CD	O	O
mg/kg/day	JJ	O	O
licofelone	NN	O	O
or	CC	O	O
5	CD	O	O
mg/kg/day	JJ	O	O
rofecoxib	NN	O	O
or	CC	O	O
no	DT	O	O
treatment	NN	O	O
during	IN	O	O
4	CD	O	O
weeks	NNS	O	O
with	IN	O	O
atherogenic	JJ	O	O
diet	NNS	O	O
in	IN	O	O
all	DT	O	O
cases	NNS	O	O
.	.	O	O

Ten	CD	O	O
healthy	JJ	O	O
rabbits	NNS	O	O
were	VBD	O	O
used	VBN	O	O
as	IN	O	O
controls	NNS	O	O
.	.	O	O

Neutrophils	NNS	O	O
and	CC	O	O
platelets	NNS	O	O
were	VBD	O	O
isolated	VBN	O	O
from	IN	O	O
peripheral	JJ	O	O
blood	NN	O	O
of	IN	O	O
rabbits	NNS	O	O
for	IN	O	O
ex	NN	O	O
vivo	NN	O	O
studies	NNS	O	O
.	.	O	O

Licofelone	NN	O	O
reduced	VBD	O	O
intima/media	JJ	O	O
ratio	NN	O	O
in	IN	O	O
injured	JJ	O	O
arteries	NNS	O	O
,	,	O	O
the	DT	O	O
macrophages	NNS	O	O
infiltration	NN	O	O
in	IN	O	O
the	DT	O	O
neointimal	JJ	O	O
area	NN	O	O
,	,	O	O
monocyte	JJ	O	O
chemoattractant	JJ	O	O
protein-1	NN	O	O
(	(	O	O
MCP-1	NNP	O	O
)	)	O	O
gene	NN	O	O
expression	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
activation	NN	O	O
of	IN	O	O
nuclear	JJ	O	O
factor-kappaB	NN	O	O
in	IN	O	O
rabbit	NN	O	O
atheroma	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
licofelone	RB	O	O
inhibited	VBN	O	O
COX-2	NNP	O	O
and	CC	O	O
5-LOX	JJ	O	O
protein	NN	O	O
expression	NN	O	O
in	IN	O	O
vascular	JJ	O	O
lesions	NNS	O	O
.	.	O	O

Rofecoxib	NNP	O	O
only	RB	O	O
diminished	VBD	O	O
COX-2	NNP	O	O
protein	NN	O	O
expression	NN	O	O
and	CC	O	O
MCP-1	NNP	O	O
gene	NN	O	O
expression	NN	O	O
in	IN	O	O
vascular	JJ	O	O
atheroma	NN	O	O
.	.	O	O

Prostaglandin	NNP	O	O
E	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
in	IN	O	O
rabbit	NN	O	O
plasma	NN	O	O
was	VBD	O	O
attenuated	VBN	O	O
by	IN	O	O
both	DT	O	O
drugs	NNS	O	O
.	.	O	O

Licofelone	NNP	O	O
almost	RB	O	O
abolished	VBD	O	O
5-LOX	JJ	O	B-enzyme
activity	NN	O	O
by	IN	O	O
inhibiting	VBG	O	O
leukotriene	JJ	O	B-PRODUCT-OF
B4	NNP	O	I-PRODUCT-OF
generation	NN	O	O
in	IN	O	O
rabbit	NN	O	O
neutrophils	NNS	O	O
and	CC	O	O
prevented	JJ	O	O
platelet	NN	O	O
thromboxane	NN	O	B-PRODUCT-OF
B2	NNP	O	I-PRODUCT-OF
production	NN	O	O
from	IN	O	O
whole	JJ	O	O
blood	NN	O	O
.	.	O	O

Licofelone	NN	O	O
reduces	VBZ	O	O
neointimal	JJ	O	O
formation	NN	O	O
and	CC	O	O
inflammation	NN	O	O
in	IN	O	O
an	DT	O	O
atherosclerotic	JJ	O	O
rabbit	NN	O	O
model	NN	O	O
more	RBR	O	O
markedly	RB	O	O
than	IN	O	O
rofecoxib	NN	O	O
.	.	O	O

This	DT	O	O
effect	NN	O	O
,	,	O	O
together	RB	O	O
with	IN	O	O
the	DT	O	O
antiplatelet	NN	O	O
activity	NN	O	O
of	IN	O	O
licofelone	NN	O	O
,	,	O	O
suggests	VBZ	O	O
that	IN	O	O
this	DT	O	O
drug	NN	O	O
may	MD	O	O
have	VB	O	O
a	DT	O	O
favorable	JJ	O	O
cardiovascular	JJ	O	O
profile	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Adenine	NNP	O	B-enzyme
phosphoribosyltransferase	NN	O	I-enzyme
plays	VBZ	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
purine	JJ	O	O
salvage	NN	O	O
by	IN	O	O
catalyzing	VBG	O	O
the	DT	O	O
direct	JJ	O	O
conversion	NN	O	O
of	IN	O	O
adenine	NN	O	B-SUBSTRATE
to	TO	O	O
adenosine	VB	O	B-PRODUCT-OF
monophosphate	NN	O	I-PRODUCT-OF
.	.	O	O

The	DT	O	O
involvement	NN	O	O
of	IN	O	O
the	DT	O	O
purine	NN	O	O
salvage	NN	O	O
pathway	NN	O	O
in	IN	O	O
tumor	NN	O	O
proliferation	NN	O	O
and	CC	O	O
angiogenesis	NN	O	O
makes	VBZ	O	O
adenine	JJ	O	O
phosphoribosyltransferase	VB	O	O
a	DT	O	O
potential	JJ	O	O
target	NN	O	O
for	IN	O	O
oncology	JJ	O	O
drug	NN	O	O
discovery	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
expressed	VBN	O	O
and	CC	O	O
characterized	VBN	O	O
recombinant	NN	O	O
,	,	O	O
N-terminally	RB	O	O
His-tagged	NNP	O	O
human	JJ	O	O
adenine	NN	O	O
phosphoribosyltransferase	NN	O	O
.	.	O	O

Two	CD	O	O
assay	VBP	O	O
formats	NNS	O	O
were	VBD	O	O
assessed	VBN	O	O
for	IN	O	O
use	NN	O	O
in	IN	O	O
a	DT	O	O
high	JJ	O	O
throughput	NN	O	O
screen	NN	O	O
:	:	O	O
a	DT	O	O
spectrophotometric-based	JJ	O	O
enzyme-coupled	JJ	O	O
assay	NN	O	O
system	NN	O	O
and	CC	O	O
a	DT	O	O
radiometric	JJ	O	O
ionic	JJ	O	O
capture	NN	O	O
scintillation	NN	O	O
proximity	NN	O	O
bead	VBP	O	O
assay	JJ	O	O
format	NN	O	O
.	.	O	O

Ultimately	RB	O	O
,	,	O	O
the	DT	O	O
scintillation	NN	O	O
proximity	NN	O	O
assay	VBP	O	O
format	NN	O	O
was	VBD	O	O
chosen	VBN	O	O
because	IN	O	O
of	IN	O	O
automated	JJ	O	O
screening	VBG	O	O
compatibility	NN	O	O
limitations	NNS	O	O
of	IN	O	O
the	DT	O	O
coupled	JJ	O	O
assay	NN	O	O
.	.	O	O

We	PRP	O	O
describe	VBP	O	O
here	RB	O	O
the	DT	O	O
biochemical	JJ	O	O
characterization	NN	O	O
of	IN	O	O
adenine	JJ	O	O
phosphoribosyltransferase	NN	O	O
and	CC	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
a	DT	O	O
robust	JJ	O	O
,	,	O	O
homogeneous	JJ	O	O
,	,	O	O
384-well	JJ	O	O
assay	NN	O	O
suitable	NN	O	O
for	IN	O	O
high	JJ	O	O
throughput	NN	O	O
screening	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
etiology	NN	O	O
of	IN	O	O
preeclampsia	NN	O	O
is	VBZ	O	O
unknown	JJ	O	O
but	CC	O	O
is	VBZ	O	O
thought	VBN	O	O
to	TO	O	O
be	VB	O	O
related	VBN	O	O
to	TO	O	O
hypoxia	VB	O	O
in	IN	O	O
the	DT	O	O
placenta	NN	O	O
.	.	O	O

We	PRP	O	O
previously	RB	O	O
reported	VBD	O	O
that	IN	O	O
the	DT	O	O
enzyme	NN	O	O
lactate	NN	O	O
dehydrogenase	NN	O	O
(	(	O	O
LDH	NNP	O	O
)	)	O	O
has	VBZ	O	O
increased	VBN	O	O
activity	NN	O	O
and	CC	O	O
gene	NN	O	O
expression	NN	O	O
in	IN	O	O
placentas	NNS	O	O
from	IN	O	O
preeclamptic	JJ	O	O
pregnancies	NNS	O	O
[	VBP	O	O
Tsoi	NNP	O	O
SCM	NNP	O	O
,	,	O	O
Zheng	NNP	O	O
J	NNP	O	O
,	,	O	O
Xu	NNP	O	O
F	NNP	O	O
,	,	O	O
Kay	NNP	O	O
HH	NNP	O	O
.	.	O	O

Differential	JJ	O	O
expression	NN	O	O
of	IN	O	O
lactate	JJ	O	O
dehydrogenase	NN	O	O
isozymes	NNS	O	O
(	(	O	O
LDH	NNP	O	O
)	)	O	O
in	IN	O	O
human	JJ	O	O
placenta	NN	O	O
with	IN	O	O
high	JJ	O	O
expression	NN	O	O
of	IN	O	O
LDH-A	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
isozyme	NN	O	O
in	IN	O	O
the	DT	O	O
endothelial	JJ	O	O
cells	NNS	O	O
of	IN	O	O
pre-eclampsia	JJ	O	O
villi	NN	O	O
.	.	O	O

Placenta	NNP	O	O
2001	CD	O	O
;	:	O	O
22:317-22	JJ	O	O
]	NN	O	O
.	.	O	O

LDH	NNP	O	B-enzyme
is	VBZ	O	O
responsible	JJ	O	O
for	IN	O	O
pyruvate	JJ	O	B-SUBSTRATE
conversion	NN	O	O
to	TO	O	O
lactate	VB	O	B-PRODUCT-OF
through	IN	O	O
glycolysis	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
further	RB	O	O
investigated	VBD	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
hypoxia	NN	O	O
in	IN	O	O
primary	JJ	O	O
trophoblast	NN	O	O
cells	NNS	O	O
and	CC	O	O
a	DT	O	O
cultured	VBN	O	O
cell	NN	O	O
line	NN	O	O
,	,	O	O
JEG3	NNP	O	O
cells	NNS	O	O
,	,	O	O
to	TO	O	O
obtain	VB	O	O
a	DT	O	O
better	JJR	O	O
understanding	NN	O	O
of	IN	O	O
how	WRB	O	O
it	PRP	O	O
affects	VBZ	O	O
the	DT	O	O
activities	NNS	O	O
of	IN	O	O
lactate	NN	O	O
dehydrogenase	NN	O	O
,	,	O	O
lactate	JJ	O	O
production	NN	O	O
and	CC	O	O
regulatory	JJ	O	O
genes	NNS	O	O
,	,	O	O
as	IN	O	O
a	DT	O	O
possible	JJ	O	O
model	NN	O	O
for	IN	O	O
preeclampsia	NN	O	O
.	.	O	O

Primary	JJ	O	O
trophoblast	NN	O	O
cells	NNS	O	O
and	CC	O	O
JEG3	NNP	O	O
cells	NNS	O	O
were	VBD	O	O
cultured	VBN	O	O
under	IN	O	O
1	CD	O	O
%	NN	O	O
oxygen	NN	O	O
.	.	O	O

At	IN	O	O
6	CD	O	O
,	,	O	O
12	CD	O	O
and	CC	O	O
24h	CD	O	O
,	,	O	O
cells	NNS	O	O
were	VBD	O	O
analyzed	VBN	O	O
for	IN	O	O
LDHA	NNP	O	O
and	CC	O	O
LDHB	NNP	O	O
isozyme	NN	O	O
activities	NNS	O	O
,	,	O	O
mRNA	NN	O	O
and	CC	O	O
protein	NN	O	O
expression	NN	O	O
compared	VBN	O	O
to	TO	O	O
standard	JJ	O	O
culture	NN	O	O
conditions	NNS	O	O
.	.	O	O

Lactate	NNP	O	O
was	VBD	O	O
measured	VBN	O	O
from	IN	O	O
cell	NN	O	O
medium	NN	O	O
.	.	O	O

The	DT	O	O
hypoxia	NN	O	O
inducible	JJ	O	O
transcription	NN	O	O
factor	NN	O	O
(	(	O	O
HIF-1alpha	NNP	O	O
)	)	O	O
protein	NN	O	O
expression	NN	O	O
was	VBD	O	O
confirmed	VBN	O	O
by	IN	O	O
western	JJ	O	O
blot	NN	O	O
.	.	O	O

Two	CD	O	O
lactate	JJ	O	O
transporters	NNS	O	O
(	(	O	O
MCT1	NNP	O	O
and	CC	O	O
MCT4	NNP	O	O
)	)	O	O
mRNA	NN	O	O
and	CC	O	O
protein	JJ	O	O
expression	NN	O	O
were	VBD	O	O
also	RB	O	O
studied	VBN	O	O
under	IN	O	O
hypoxia	NN	O	O
.	.	O	O

Finally	RB	O	O
,	,	O	O
lactate	NN	O	O
was	VBD	O	O
measured	VBN	O	O
in	IN	O	O
plasma	NN	O	O
obtained	VBN	O	O
from	IN	O	O
patients	NNS	O	O
with	IN	O	O
severe	JJ	O	O
preeclampsia	NN	O	O
.	.	O	O

Under	IN	O	O
hypoxic	JJ	O	O
conditions	NNS	O	O
,	,	O	O
LDHA	NNP	O	O
mRNA	NN	O	O
is	VBZ	O	O
increased	VBN	O	O
in	IN	O	O
primary	JJ	O	O
trophoblast	NN	O	O
cells	NNS	O	O
and	CC	O	O
JEG3	NNP	O	O
cells	NNS	O	O
.	.	O	O

The	DT	O	O
HIF-1alpha	NNP	O	O
protein	NN	O	O
expression	NN	O	O
is	VBZ	O	O
higher	JJR	O	O
in	IN	O	O
hypoxia-treated	JJ	O	O
JEG3	NNP	O	O
cells	NNS	O	O
than	IN	O	O
control	NN	O	O
.	.	O	O

LDHA	NNP	O	O
isozyme	NN	O	O
activity	NN	O	O
and	CC	O	O
its	PRP$	O	O
protein	NN	O	O
expression	NN	O	O
are	VBP	O	O
increased	VBN	O	O
most	JJS	O	O
significantly	RB	O	O
at	IN	O	O
24h	CD	O	O
of	IN	O	O
culture	NN	O	O
under	IN	O	O
hypoxia	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
LDHB	NNP	O	O
protein	NN	O	O
is	VBZ	O	O
unchanged	JJ	O	O
while	IN	O	O
its	PRP$	O	O
mRNA	NN	O	O
is	VBZ	O	O
decreased	VBN	O	O
.	.	O	O

Lactate	NNP	O	O
secretion	NN	O	O
from	IN	O	O
JEG3	NNP	O	O
cells	NNS	O	O
under	IN	O	O
hypoxia	NN	O	O
is	VBZ	O	O
increased	VBN	O	O
,	,	O	O
as	IN	O	O
is	VBZ	O	O
the	DT	O	O
lactate	NN	O	O
levels	NNS	O	O
in	IN	O	O
the	DT	O	O
plasma	NN	O	O
from	IN	O	O
preeclampsia	NN	O	O
patients	NNS	O	O
.	.	O	O

Of	IN	O	O
the	DT	O	O
two	CD	O	O
lactate	NN	O	O
transporters	NNS	O	O
studied	VBD	O	O
,	,	O	O
MCT4	NNP	O	O
mRNA	NN	O	O
and	CC	O	O
protein	NN	O	O
level	NN	O	O
are	VBP	O	O
increased	VBN	O	O
under	IN	O	O
hypoxia	NN	O	O
.	.	O	O

Our	PRP$	O	O
findings	NNS	O	O
support	VBP	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
hypoxia	NN	O	O
in	IN	O	O
inducing	VBG	O	O
HIF-1alpha	JJ	O	O
activity	NN	O	O
in	IN	O	O
trophoblasts	NNS	O	O
and	CC	O	O
increasing	VBG	O	O
LDH	NNP	O	O
transcription	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
its	PRP$	O	O
activity	NN	O	O
.	.	O	O

Higher	JJR	O	O
levels	NNS	O	O
of	IN	O	O
lactate	NN	O	O
are	VBP	O	O
produced	VBN	O	O
and	CC	O	O
secreted	VBN	O	O
which	WDT	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
the	DT	O	O
higher	JJR	O	O
lactate	NN	O	O
levels	NNS	O	O
in	IN	O	O
plasma	NN	O	O
of	IN	O	O
preeclamptic	JJ	O	O
patients	NNS	O	O
.	.	O	O

These	DT	O	O
mechanisms	NNS	O	O
may	MD	O	O
be	VB	O	O
important	JJ	O	O
in	IN	O	O
the	DT	O	O
pathophysiology	NN	O	O
of	IN	O	O
preeclampsia	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

In	IN	O	O
kidneys	NNS	O	O
,	,	O	O
stimulation	NN	O	O
of	IN	O	O
adenylyl	JJ	O	O
cyclase	NN	O	O
causes	VBZ	O	O
egress	NN	O	O
of	IN	O	O
cAMP	NN	O	O
,	,	O	O
conversion	NN	O	O
of	IN	O	O
cAMP	NN	O	B-SUBSTRATE
to	TO	O	O
AMP	NNP	O	B-PRODUCT-OF
by	IN	O	O
ecto-phosphodiesterase	NN	O	O
,	,	O	O
and	CC	O	O
metabolism	NN	O	O
of	IN	O	O
AMP	NNP	O	B-SUBSTRATE
to	TO	O	O
adenosine	VB	O	B-PRODUCT-OF
by	IN	O	O
ecto-5'-nucleotidase	NN	O	B-enzyme
.	.	O	O

Although	IN	O	O
much	JJ	O	O
is	VBZ	O	O
known	VBN	O	O
about	IN	O	O
ecto-5'-nucleotidase	NN	O	O
,	,	O	O
the	DT	O	O
renal	JJ	O	O
ecto-phosphodiesterase	NN	O	O
remains	VBZ	O	O
uncharacterized	JJ	O	O
.	.	O	O

We	PRP	O	O
administered	VBD	O	O
cAMP	NN	O	O
(	(	O	O
10	CD	O	O
microM	NN	O	O
in	IN	O	O
the	DT	O	O
perfusate	NN	O	O
)	)	O	O
to	TO	O	O
12	CD	O	O
different	JJ	O	O
groups	NNS	O	O
of	IN	O	O
perfused	JJ	O	O
kidneys	NNS	O	O
.	.	O	O

AMP	NNP	O	O
was	VBD	O	O
measured	VBN	O	O
in	IN	O	O
perfusate	NN	O	O
using	VBG	O	O
ion	NN	O	O
trap	NN	O	O
mass	NN	O	O
spectrometry	NN	O	O
.	.	O	O

In	IN	O	O
control	NN	O	O
kidneys	NNS	O	O
(	(	O	O
n=19	NN	O	O
)	)	O	O
,	,	O	O
basal	JJ	O	O
renal	JJ	O	O
secretion	NN	O	O
rate	NN	O	O
of	IN	O	O
AMP	NNP	O	O
was	VBD	O	O
0.49+/-0.08	JJ	O	O
and	CC	O	O
increased	VBD	O	O
to	TO	O	O
3.0+/-0.2	JJ	O	O
nmol	JJ	O	O
AMP/g	NNP	O	O
kidney	NN	O	O
weight/min	NN	O	O
during	IN	O	O
administration	NN	O	O
of	IN	O	O
cAMP	NN	O	O
.	.	O	O

A	DT	O	O
broad-spectrum	JJ	O	O
phosphodiesterase	NN	O	O
(	(	O	O
PDE	NNP	O	O
)	)	O	O
inhibitor	NN	O	O
(	(	O	O
1,3-isobutyl-1-methylxanthine	JJ	O	O
,	,	O	O
300	CD	O	O
microM	NN	O	O
,	,	O	O
n=6	NN	O	O
)	)	O	O
and	CC	O	O
an	DT	O	O
ecto-phosphodiesterase	JJ	O	O
inhibitor	NN	O	O
(	(	O	O
1,3-dipropyl-8-p-sulfophenylxanthine	JJ	O	O
,	,	O	O
1	CD	O	O
mM	NN	O	O
,	,	O	O
n=6	NN	O	O
)	)	O	O
significantly	RB	O	O
attenuated	VBN	O	O
cAMP-induced	JJ	O	O
AMP	NNP	O	O
secretion	NN	O	O
by	IN	O	O
60	CD	O	O
and	CC	O	O
74	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Blockade	NN	O	O
of	IN	O	O
PDE1	NNP	O	O
(	(	O	O
8-methoxymethyl-3-isobutyl-1-methylxanthine	JJ	O	O
,	,	O	O
100	CD	O	O
microM	NN	O	O
)	)	O	O
,	,	O	O
PDE2	NNP	O	O
[	NNP	O	O
erythro-9-	JJ	O	O
(	(	O	O
2-hydroxy-3-nonyl	JJ	O	O
)	)	O	O
adenine	NN	O	O
,	,	O	O
30	CD	O	O
microM	NN	O	O
]	NN	O	O
,	,	O	O
PDE3	NNP	O	O
(	(	O	O
milrinone	NN	O	O
,	,	O	O
10	CD	O	O
microM	NN	O	O
;	:	O	O
cGMP	NN	O	O
,	,	O	O
10	CD	O	O
microM	NN	O	O
)	)	O	O
,	,	O	O
PDE4	NNP	O	O
(	(	O	O
Ro	NNP	O	O
20-1724	CD	O	O
[	NNP	O	O
4-	CD	O	O
(	(	O	O
3-butoxy-4-methoxybenzyl	CD	O	O
)	)	O	O
imidazolidin-2-one	NN	O	O
]	NN	O	O
,	,	O	O
100	CD	O	O
microM	NN	O	O
)	)	O	O
,	,	O	O
PDE5	NNP	O	O
and	CC	O	O
PDE6	NNP	O	O
(	(	O	O
zaprinast	NN	O	O
,	,	O	O
30	CD	O	O
microM	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
PDE7	NNP	O	O
[	NNP	O	O
BRL-50481	NNP	O	O
(	(	O	O
5-nitro-2	JJ	O	O
,	,	O	O
N	NNP	O	O
,	,	O	O
N-trimethylbenzenesulfonamide	NNP	O	O
)	)	O	O
,	,	O	O
10	CD	O	O
microM	NN	O	O
]	NN	O	O
did	VBD	O	O
not	RB	O	O
alter	VB	O	O
renal	JJ	O	O
ecto-phosphodiesterase	JJ	O	O
activity	NN	O	O
.	.	O	O

Administration	NN	O	O
of	IN	O	O
a	DT	O	O
concentration	NN	O	O
(	(	O	O
100	CD	O	O
microM	NN	O	O
)	)	O	O
of	IN	O	O
dipyridamole	NN	O	O
that	IN	O	O
blocks	VBZ	O	O
PDE8	NNP	O	O
inhibited	VBD	O	O
ecto-phosphodiesterase	JJ	O	O
activity	NN	O	O
(	(	O	O
by	IN	O	O
44	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
a	DT	O	O
lower	JJR	O	O
concentration	NN	O	O
of	IN	O	O
dipyridamole	NN	O	O
(	(	O	O
3	CD	O	O
microM	NN	O	O
)	)	O	O
that	WDT	O	O
blocks	VBZ	O	O
PDE9	NNP	O	O
,	,	O	O
PDE10	NNP	O	O
,	,	O	O
and	CC	O	O
PDE11	NNP	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
PDE8	NNP	O	O
,	,	O	O
did	VBD	O	O
not	RB	O	O
inhibit	VB	O	O
ecto-phosphodiesterase	JJ	O	O
activity	NN	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
support	NN	O	O
the	DT	O	O
conclusion	NN	O	O
that	IN	O	O
renal	JJ	O	O
ecto-phosphodiesterase	JJ	O	O
activity	NN	O	O
is	VBZ	O	O
not	RB	O	O
mediated	VBN	O	O
by	IN	O	O
PDE1	NNP	O	O
,	,	O	O
PDE2	NNP	O	O
,	,	O	O
PDE3	NNP	O	O
,	,	O	O
PDE4	NNP	O	O
,	,	O	O
PDE5	NNP	O	O
,	,	O	O
PDE6	NNP	O	O
,	,	O	O
PDE7	NNP	O	O
,	,	O	O
PDE9	NNP	O	O
,	,	O	O
PDE10	NNP	O	O
,	,	O	O
or	CC	O	O
PDE11	NNP	O	O
and	CC	O	O
is	VBZ	O	O
inhibited	VBN	O	O
by	IN	O	O
high	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
dipyridamole	NN	O	O
.	.	O	O

Ecto-phosphodiesterase	NNP	O	O
has	VBZ	O	O
some	DT	O	O
pharmacological	JJ	O	O
characteristics	NNS	O	O
similar	JJ	O	O
to	TO	O	O
PDE8	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

This	DT	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
inward	JJ	O	O
transport	NN	O	O
of	IN	O	O
l-	JJ	O	B-SUBSTRATE
[	NNP	O	O
(	(	O	O
14	CD	O	O
)	)	O	O
C	NNP	O	O
]	NNP	O	O
alanine	NN	O	O
,	,	O	O
an	DT	O	O
ASCT2	NNP	O	B-enzyme
preferential	JJ	O	O
substrate	NN	O	O
,	,	O	O
in	IN	O	O
monolayers	NNS	O	O
of	IN	O	O
immortalized	JJ	O	O
renal	JJ	O	O
proximal	NN	O	O
tubular	JJ	O	O
epithelial	NN	O	O
(	(	O	O
PTE	NNP	O	O
)	)	O	O
cells	NNS	O	O
from	IN	O	O
Wistar-Kyoto	NNP	O	O
(	(	O	O
WKY	NNP	O	O
)	)	O	O
and	CC	O	O
spontaneously	RB	O	O
hypertensive	JJ	O	O
(	(	O	O
SHR	NNP	O	O
)	)	O	O
rats	NNS	O	O
.	.	O	O

The	DT	O	O
expression	NN	O	O
of	IN	O	O
ASCT2	NNP	O	O
in	IN	O	O
WKY	NNP	O	O
and	CC	O	O
SHR	NNP	O	O
PTE	NNP	O	O
cells	NNS	O	O
and	CC	O	O
kidney	NN	O	O
cortices	NNS	O	O
from	IN	O	O
WKY	NNP	O	O
and	CC	O	O
SHR	NNP	O	O
was	VBD	O	O
also	RB	O	O
evaluated	VBN	O	O
.	.	O	O

l-	JJ	O	O
[	NNP	O	O
(	(	O	O
14	CD	O	O
)	)	O	O
C	NNP	O	O
]	NNP	O	O
alanine	JJ	O	O
uptake	NN	O	O
was	VBD	O	O
highly	RB	O	O
dependent	JJ	O	O
on	IN	O	O
extracellular	JJ	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
.	.	O	O

Replacement	NN	O	O
of	IN	O	O
NaCl	NNP	O	O
by	IN	O	O
LiCl	NNP	O	O
or	CC	O	O
choline	VB	O	O
chloride	NN	O	O
abolished	VBD	O	O
transport	NN	O	O
activity	NN	O	O
in	IN	O	O
SHR	NNP	O	O
and	CC	O	O
WKY	NNP	O	O
PTE	NNP	O	O
cells	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
the	DT	O	O
system	NN	O	O
L	NNP	O	O
inhibitor	NN	O	O
BCH	NNP	O	O
,	,	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
-dependent	VBD	O	O
l-alanine	JJ	O	B-SUBSTRATE
uptake	NN	O	O
in	IN	O	O
WKY	NNP	O	O
and	CC	O	O
SHR	NNP	O	O
PTE	NNP	O	O
cells	NNS	O	O
was	VBD	O	O
inhibited	VBN	O	O
by	IN	O	O
alanine	NN	O	O
,	,	O	O
serine	NN	O	O
,	,	O	O
and	CC	O	O
cysteine	NN	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
consistent	JJ	O	O
with	IN	O	O
amino	NN	O	B-SUBSTRATE
acid	NN	O	I-SUBSTRATE
transport	NN	O	O
through	IN	O	O
ASCT2	NNP	O	B-enzyme
.	.	O	O

The	DT	O	O
saturable	JJ	O	O
component	NN	O	O
of	IN	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
-dependent	VBD	O	O
l-alanine	JJ	O	O
transport	NN	O	O
under	IN	O	O
V	NNP	O	O
(	(	O	O
max	NN	O	O
)	)	O	O
conditions	NNS	O	O
in	IN	O	O
SHR	NNP	O	O
PTE	NNP	O	O
cells	NNS	O	O
was	VBD	O	O
one-half	NN	O	O
of	IN	O	O
that	DT	O	O
in	IN	O	O
WKY	NNP	O	O
PTE	NNP	O	O
cells	NNS	O	O
,	,	O	O
with	IN	O	O
similar	JJ	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
values	NNS	O	O
.	.	O	O

Differences	NNS	O	O
in	IN	O	O
magnitude	NN	O	O
of	IN	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
-dependent	VBD	O	O
l-alanine	JJ	O	B-SUBSTRATE
uptake	NN	O	O
through	IN	O	O
ASCT2	NNP	O	B-enzyme
between	IN	O	O
WKY	NNP	O	O
and	CC	O	O
SHR	NNP	O	O
PTE	NNP	O	O
cells	NNS	O	O
correlated	VBD	O	O
positively	RB	O	O
with	IN	O	O
differences	NNS	O	O
in	IN	O	O
ASCT2	NNP	O	O
protein	NN	O	O
expression	NN	O	O
,	,	O	O
this	DT	O	O
being	VBG	O	O
more	RBR	O	O
abundant	JJ	O	O
in	IN	O	O
WKY	NNP	O	O
PTE	NNP	O	O
cells	NNS	O	O
.	.	O	O

Abundance	NN	O	O
of	IN	O	O
ASCT2	NNP	O	O
transcript	NN	O	O
and	CC	O	O
protein	NN	O	O
in	IN	O	O
kidney	NN	O	O
cortices	NNS	O	O
of	IN	O	O
SHR	NNP	O	O
rats	NN	O	O
was	VBD	O	O
also	RB	O	O
lower	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
normotensive	JJ	O	O
WKY	NNP	O	O
rats	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
immortalized	VBN	O	O
SHR	NNP	O	O
and	CC	O	O
WKY	NNP	O	O
PTE	NNP	O	O
cells	NNS	O	O
take	VBP	O	O
up	RP	O	O
l-alanine	JJ	O	B-SUBSTRATE
mainly	RB	O	O
through	IN	O	O
a	DT	O	O
high-affinity	NN	O	O
Na	NNP	O	B-enzyme
(	(	O	O
+	NNP	O	O
)	)	O	O
-dependent	NN	O	O
amino	NN	O	I-enzyme
acid	NN	O	O
transporter	NN	O	O
,	,	O	O
with	IN	O	O
functional	JJ	O	O
features	NNS	O	O
of	IN	O	O
ASCT2	NNP	O	B-enzyme
transport	NN	O	O
.	.	O	O

The	DT	O	O
activity	NN	O	O
and	CC	O	O
expression	NN	O	O
of	IN	O	O
the	DT	O	O
ASCT2	NNP	O	O
transporter	NN	O	O
were	VBD	O	O
considerably	RB	O	O
lower	JJR	O	O
in	IN	O	O
the	DT	O	O
SHR	NNP	O	O
cells	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Prostaglandin	NNP	O	O
E	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
(	(	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
)	)	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
play	VB	O	O
important	JJ	O	O
roles	NNS	O	O
in	IN	O	O
several	JJ	O	O
aspects	NNS	O	O
of	IN	O	O
tumor	NN	O	O
development	NN	O	O
and	CC	O	O
progression	NN	O	O
.	.	O	O

PGE	NNP	O	B-PRODUCT-OF
(	(	O	O
2	CD	O	O
)	)	O	O
is	VBZ	O	O
synthesized	VBN	O	O
from	IN	O	O
arachidonic	JJ	O	B-SUBSTRATE
acid	NN	O	I-SUBSTRATE
by	IN	O	O
cyclooxygenases	NNS	O	B-enzyme
(	(	O	O
COX	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
prostaglandin	JJ	O	B-enzyme
E	NN	O	I-enzyme
synthases	NNS	O	O
(	(	O	O
PGES	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
mediates	VBZ	O	O
its	PRP$	O	O
biological	JJ	O	O
activity	NN	O	O
through	IN	O	O
binding	NN	O	O
to	TO	O	O
the	DT	O	O
four	CD	O	O
prostanoid	NN	O	O
receptors	NNS	O	O
EP	NNP	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
through	IN	O	O
EP	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
show	VBP	O	O
for	IN	O	O
the	DT	O	O
first	JJ	O	O
time	NN	O	O
that	WDT	O	O
medulloblastoma	NN	O	O
(	(	O	O
MB	NNP	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
most	RBS	O	O
common	JJ	O	O
malignant	JJ	O	O
childhood	NN	O	O
brain	NN	O	O
tumor	NN	O	O
,	,	O	O
expresses	VBZ	O	O
high	JJ	O	O
levels	NNS	O	O
of	IN	O	O
COX-2	NNP	O	O
,	,	O	O
microsomal	JJ	O	O
prostaglandin	NN	O	O
E	NNP	O	O
synthase-1	NN	O	O
,	,	O	O
and	CC	O	O
EP	NNP	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
through	IN	O	O
EP	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
and	CC	O	O
secretes	VBZ	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
.	.	O	O

PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
EP	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
receptor	NN	O	O
agonist	NN	O	O
butaprost	NN	O	O
stimulated	VBD	O	O
MB	NNP	O	O
cell	NN	O	O
proliferation	NN	O	O
.	.	O	O

Treatment	NN	O	O
of	IN	O	O
MB	NNP	O	O
cells	NNS	O	O
with	IN	O	O
COX	NNP	O	O
inhibitors	NNS	O	O
suppressed	VBD	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
production	NN	O	O
and	CC	O	O
induced	JJ	O	O
caspase-dependent	JJ	O	O
apoptosis	NN	O	O
.	.	O	O

Similarly	RB	O	O
,	,	O	O
specific	JJ	O	O
COX-2	NNP	O	O
silencing	NN	O	O
by	IN	O	O
small	JJ	O	O
interfering	VBG	O	O
RNA	NNP	O	O
inhibited	VBD	O	O
MB	NNP	O	O
cell	NN	O	O
growth	NN	O	O
.	.	O	O

EP	NNP	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
and	CC	O	O
EP	NNP	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
receptor	NN	O	O
antagonists	VBZ	O	O
ONO-8713	NNP	O	O
and	CC	O	O
ONO-AE3-240	NNP	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
the	DT	O	O
EP	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
antagonists	VBZ	O	O
ONO-AE3-208	NNP	O	O
and	CC	O	O
AH	NNP	O	O
23848	CD	O	O
,	,	O	O
inhibited	VBN	O	O
tumor	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
,	,	O	O
indicating	VBG	O	O
the	DT	O	O
significance	NN	O	O
of	IN	O	O
EP	NNP	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
and	CC	O	O
EP	NNP	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
but	CC	O	O
not	RB	O	O
EP	NNP	O	O
(	(	O	O
4	CD	O	O
)	)	O	O
for	IN	O	O
MB	NNP	O	O
growth	NN	O	O
.	.	O	O

Administration	NN	O	O
of	IN	O	O
COX	NNP	O	O
inhibitors	NNS	O	O
at	IN	O	O
clinically	RB	O	O
achievable	JJ	O	O
nontoxic	JJ	O	O
concentrations	NNS	O	O
significantly	RB	O	O
inhibited	VBD	O	O
growth	NN	O	O
of	IN	O	O
established	VBN	O	O
human	JJ	O	O
MB	NNP	O	O
xenografts	NNS	O	O
.	.	O	O

Apoptosis	NN	O	O
was	VBD	O	O
increased	VBN	O	O
,	,	O	O
proliferation	NN	O	O
was	VBD	O	O
reduced	VBN	O	O
,	,	O	O
and	CC	O	O
angiogenesis	NN	O	O
was	VBD	O	O
inhibited	VBN	O	O
in	IN	O	O
MBs	NNP	O	O
treated	VBD	O	O
with	IN	O	O
COX	NNP	O	O
inhibitors	NNS	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
is	VBZ	O	O
important	JJ	O	O
for	IN	O	O
MB	NNP	O	O
growth	NN	O	O
and	CC	O	O
that	IN	O	O
therapies	NNS	O	O
targeting	VBG	O	O
the	DT	O	O
prostanoid	NN	O	O
metabolic	JJ	O	O
pathway	NN	O	O
are	VBP	O	O
potentially	RB	O	O
beneficial	JJ	O	O
and	CC	O	O
should	MD	O	O
be	VB	O	O
tested	VBN	O	O
in	IN	O	O
clinical	JJ	O	O
settings	NNS	O	O
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
children	NNS	O	O
with	IN	O	O
MB	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Tolvaptan	NNP	O	O
is	VBZ	O	O
a	DT	O	O
selective	JJ	O	O
arginine	NN	O	O
vasopressin	NN	O	O
(	(	O	O
AVP	NNP	O	O
)	)	O	O
V	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
receptor	NN	O	O
blocker	NN	O	O
used	VBN	O	O
to	TO	O	O
induce	VB	O	O
free	JJ	O	O
water	NN	O	O
diuresis	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
euvolemic	JJ	O	O
or	CC	O	O
hypervolemic	JJ	O	O
hyponatremia	NN	O	O
.	.	O	O

Currently	RB	O	O
the	DT	O	O
orally	RB	O	O
active	JJ	O	O
medication	NN	O	O
is	VBZ	O	O
in	IN	O	O
the	DT	O	O
final	JJ	O	O
stages	NNS	O	O
prior	RB	O	O
to	TO	O	O
approval	NN	O	O
by	IN	O	O
the	DT	O	O
FDA	NNP	O	O
for	IN	O	O
outpatient	JJ	O	O
therapy	NN	O	O
.	.	O	O

It	PRP	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
safe	JJ	O	O
and	CC	O	O
effective	JJ	O	O
at	IN	O	O
promoting	VBG	O	O
aquaresis	NN	O	O
and	CC	O	O
raising	VBG	O	O
serum	JJ	O	O
sodium	NN	O	O
levels	NNS	O	O
in	IN	O	O
both	DT	O	O
short-	JJ	O	O
and	CC	O	O
long-term	JJ	O	O
studies	NNS	O	O
.	.	O	O

Tolvaptan	NNP	O	O
is	VBZ	O	O
also	RB	O	O
effective	JJ	O	O
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
congestive	JJ	O	O
heart	NN	O	O
failure	NN	O	O
(	(	O	O
CHF	NNP	O	O
)	)	O	O
exacerbation	NN	O	O
,	,	O	O
but	CC	O	O
whether	IN	O	O
there	EX	O	O
are	VBP	O	O
long	JJ	O	O
standing	VBG	O	O
beneficial	JJ	O	O
effects	NNS	O	O
on	IN	O	O
CHF	NNP	O	O
is	VBZ	O	O
still	RB	O	O
controversial	JJ	O	O
.	.	O	O

Prolonged	VBN	O	O
use	NN	O	O
of	IN	O	O
tolvaptan	JJ	O	O
leads	NNS	O	O
to	TO	O	O
increased	VBN	O	O
endogenous	JJ	O	O
levels	NNS	O	O
of	IN	O	O
AVP	NNP	O	O
and	CC	O	O
perhaps	RB	O	O
over-stimulation	NN	O	O
of	IN	O	O
V	NNP	O	O
(	(	O	O
1A	CD	O	O
)	)	O	O
receptors	NNS	O	O
.	.	O	O

Theoretically	RB	O	O
this	DT	O	O
activation	NN	O	O
could	MD	O	O
lead	VB	O	O
to	TO	O	O
increased	VBN	O	O
afterload	NN	O	O
and	CC	O	O
cardiac	JJ	O	O
myocyte	NN	O	O
fibrosis	NN	O	O
,	,	O	O
causing	VBG	O	O
progression	NN	O	O
of	IN	O	O
CHF	NNP	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
after	IN	O	O
52	CD	O	O
weeks	NNS	O	O
of	IN	O	O
tolvaptan	JJ	O	O
therapy	NN	O	O
there	EX	O	O
was	VBD	O	O
no	DT	O	O
worsening	NN	O	O
of	IN	O	O
left	JJ	O	O
ventricular	JJ	O	O
dilatation	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
tolvaptan	NN	O	B-SUBSTRATE
is	VBZ	O	O
metabolized	VBN	O	O
by	IN	O	O
the	DT	O	O
CYP3A4	NNP	O	B-enzyme
system	NN	O	O
;	:	O	O
thus	RB	O	O
physicians	NNS	O	O
should	MD	O	O
be	VB	O	O
aware	JJ	O	O
of	IN	O	O
the	DT	O	O
potential	JJ	O	O
for	IN	O	O
increased	JJ	O	O
interactions	NNS	O	O
with	IN	O	O
other	JJ	O	O
medications	NNS	O	O
.	.	O	O

Tolvaptan	NNP	O	O
is	VBZ	O	O
a	DT	O	O
breakthrough	NN	O	O
in	IN	O	O
the	DT	O	O
therapy	NN	O	O
of	IN	O	O
hyponatremia	NN	O	O
as	IN	O	O
it	PRP	O	O
directly	RB	O	O
combats	VBZ	O	O
elevated	VBN	O	O
AVP	NNP	O	O
levels	NNS	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
syndrome	NN	O	O
of	IN	O	O
inappropriate	JJ	O	O
secretion	NN	O	O
of	IN	O	O
antidiuretic	JJ	O	O
hormone	NN	O	O
,	,	O	O
congestive	JJ	O	O
heart	NN	O	O
failure	NN	O	O
,	,	O	O
and	CC	O	O
cirrhosis	NN	O	O
of	IN	O	O
the	DT	O	O
liver	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Ambrisentan	NNP	O	B-SUBSTRATE
is	VBZ	O	O
an	DT	O	O
endothelin	JJ	O	O
type	NN	O	O
A	NNP	O	O
(	(	O	O
ET	NNP	O	O
(	(	O	O
A	NNP	O	O
)	)	O	O
)	)	O	O
-selective	JJ	O	O
receptor	NN	O	O
antagonist	NN	O	O
that	WDT	O	O
is	VBZ	O	O
metabolized	VBN	O	O
primarily	RB	O	O
by	IN	O	O
glucuronidation	NN	O	O
but	CC	O	O
also	RB	O	O
undergoes	JJ	O	O
oxidative	JJ	O	O
metabolism	NN	O	O
by	IN	O	O
CYP3A4	NNP	O	B-enzyme
.	.	O	O

The	DT	O	O
potential	NN	O	O
for	IN	O	O
ketoconazole	NN	O	O
,	,	O	O
the	DT	O	O
archetypal	JJ	O	O
strong	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
CYP3A4	NNP	O	O
,	,	O	O
to	TO	O	O
alter	VB	O	O
the	DT	O	O
pharmacokinetic	JJ	O	O
profile	NN	O	O
of	IN	O	O
ambrisentan	NN	O	O
and	CC	O	O
its	PRP$	O	O
oxidative	JJ	O	O
metabolite	NN	O	O
,	,	O	O
4-hydroxymethyl	JJ	O	O
ambrisentan	NN	O	O
,	,	O	O
was	VBD	O	O
assessed	VBN	O	O
in	IN	O	O
an	DT	O	O
open-label	JJ	O	O
,	,	O	O
nonrandomized	JJ	O	O
,	,	O	O
2-period	JJ	O	O
,	,	O	O
single-sequence	JJ	O	O
study	NN	O	O
in	IN	O	O
16	CD	O	O
healthy	JJ	O	O
men	NNS	O	O
.	.	O	O

Participants	NNS	O	O
received	VBD	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
of	IN	O	O
ambrisentan	JJ	O	O
10	CD	O	O
mg	NN	O	O
alone	RB	O	O
and	CC	O	O
after	IN	O	O
4	CD	O	O
days	NNS	O	O
of	IN	O	O
ketoconazole	JJ	O	O
400	CD	O	O
mg	NN	O	O
administered	VBN	O	O
once	RB	O	O
daily	JJ	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
multiple	JJ	O	O
doses	NNS	O	O
of	IN	O	O
ketoconazole	NN	O	O
,	,	O	O
single-dose	JJ	O	O
ambrisentan	NN	O	O
AUC	NNP	O	O
(	(	O	O
0-infinity	NN	O	O
)	)	O	O
estimate	NN	O	O
was	VBD	O	O
increased	VBN	O	O
by	IN	O	O
35.3	CD	O	O
%	NN	O	O
,	,	O	O
whereas	JJ	O	O
C	NNP	O	O
(	(	O	O
max	NN	O	O
)	)	O	O
was	VBD	O	O
increased	VBN	O	O
by	IN	O	O
20.0	CD	O	O
%	NN	O	O
.	.	O	O

For	IN	O	O
the	DT	O	O
4-hydroxymethyl	JJ	O	O
ambrisentan	NN	O	O
metabolite	NN	O	O
,	,	O	O
AUC	NNP	O	O
(	(	O	O
0-infinity	NN	O	O
)	)	O	O
estimate	NN	O	O
was	VBD	O	O
decreased	VBN	O	O
by	IN	O	O
4.0	CD	O	O
%	NN	O	O
,	,	O	O
whereas	JJ	O	O
C	NNP	O	O
(	(	O	O
max	NN	O	O
)	)	O	O
was	VBD	O	O
decreased	VBN	O	O
by	IN	O	O
16.5	CD	O	O
%	NN	O	O
.	.	O	O

Concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
ambrisentan	JJ	O	O
and	CC	O	O
ketoconazole	NN	O	O
was	VBD	O	O
well	RB	O	O
tolerated	VBN	O	O
.	.	O	O

In	IN	O	O
summary	JJ	O	O
,	,	O	O
ketoconazole	VB	O	O
had	VBD	O	O
no	DT	O	O
clinically	RB	O	O
significant	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
pharmacokinetics	NNS	O	O
or	CC	O	O
safety	NN	O	O
profile	NN	O	O
of	IN	O	O
ambrisentan	NN	O	O
;	:	O	O
therefore	RB	O	O
,	,	O	O
no	DT	O	O
changes	NNS	O	O
in	IN	O	O
ambrisentan	NN	O	O
dose	NN	O	O
should	MD	O	O
be	VB	O	O
necessary	JJ	O	O
when	WRB	O	O
the	DT	O	O
drug	NN	O	O
is	VBZ	O	O
administered	VBN	O	O
concomitantly	RB	O	O
with	IN	O	O
known	VBN	O	O
CYP3A4	NNP	O	O
inhibitors	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Vitamin	NNP	O	O
E	NNP	O	O
(	(	O	O
alpha-tocopherol	NN	O	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
essential	JJ	O	O
fat-soluble	JJ	O	O
nutrient	NN	O	O
with	IN	O	O
antioxidant	JJ	O	O
properties	NNS	O	O
.	.	O	O

alpha-Tocopherol	NN	O	B-enzyme
transfer	NN	O	I-enzyme
protein	NN	O	O
(	(	O	O
alpha-TTP	JJ	O	B-enzyme
)	)	O	O
,	,	O	O
the	DT	O	O
product	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
responsible	JJ	O	O
for	IN	O	O
familial	JJ	O	O
isolated	JJ	O	O
vitamin	NN	O	O
E	NNP	O	O
deficiency	NN	O	O
,	,	O	O
plays	VBZ	O	O
an	DT	O	O
important	JJ	O	O
role	NN	O	O
in	IN	O	O
maintaining	VBG	O	O
the	DT	O	O
plasma	JJ	O	O
alpha-tocopherol	JJ	O	B-SUBSTRATE
level	NN	O	O
by	IN	O	O
mediating	VBG	O	O
the	DT	O	O
secretion	NN	O	O
of	IN	O	O
alpha-tocopherol	NN	O	B-SUBSTRATE
by	IN	O	O
the	DT	O	O
liver	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
mechanisms	NNS	O	O
underlying	VBG	O	O
hepatic	JJ	O	O
alpha-tocopherol	JJ	O	O
secretion	NN	O	O
are	VBP	O	O
not	RB	O	O
fully	RB	O	O
understood	JJ	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
undertaken	VBN	O	O
to	TO	O	O
elucidate	VB	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
alpha-tocopherol	JJ	O	O
re-efflux	NN	O	O
from	IN	O	O
hepatocytes	NNS	O	O
,	,	O	O
the	DT	O	O
cells	NNS	O	O
that	WDT	O	O
have	VBP	O	O
the	DT	O	O
most	RBS	O	O
important	JJ	O	O
role	NN	O	O
in	IN	O	O
regulating	VBG	O	O
plasma-alpha-tocopherol	JJ	O	O
concentrations	NNS	O	O
.	.	O	O

From	IN	O	O
in	IN	O	O
vitro	NN	O	O
experiments	NNS	O	O
using	VBG	O	O
[	NNP	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
H	NNP	O	O
]	NNP	O	O
alpha-tocopheryl	JJ	O	O
acetate	NN	O	O
and	CC	O	O
McARH7777	NNP	O	O
cells	NNS	O	O
that	WDT	O	O
stably	RB	O	O
express	VBP	O	O
alpha-tocopherol	JJ	O	O
transfer	NN	O	O
protein	NN	O	O
(	(	O	O
alpha-TTP	JJ	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
following	JJ	O	O
results	NNS	O	O
were	VBD	O	O
obtained	VBN	O	O
.	.	O	O

First	RB	O	O
,	,	O	O
addition	NN	O	O
of	IN	O	O
apolipoprotein	JJ	O	B-enzyme
A-I	NNP	O	I-enzyme
(	(	O	O
apoA-I	NN	O	B-enzyme
)	)	O	O
,	,	O	O
a	DT	O	O
direct	JJ	O	O
acceptor	NN	O	O
of	IN	O	O
the	DT	O	O
ATP-binding	NNP	O	B-enzyme
cassette	NN	O	I-enzyme
transporter	NN	O	O
A1	NNP	O	O
(	(	O	O
ABCA1	NNP	O	B-enzyme
)	)	O	O
-secreted	VBD	O	O
lipids	NNS	O	O
,	,	O	O
increased	VBD	O	O
alpha-tocopherol	JJ	O	B-PRODUCT-OF
secretion	NN	O	O
in	IN	O	O
a	DT	O	O
dose-dependent	JJ	O	O
manner	NN	O	O
.	.	O	O

Second	JJ	O	O
,	,	O	O
probucol	NN	O	O
,	,	O	O
an	DT	O	O
antiatherogenic	JJ	O	O
compound	NN	O	O
reported	VBD	O	O
to	TO	O	O
be	VB	O	O
an	DT	O	O
inactivator	NN	O	O
of	IN	O	O
ABCA1	NNP	O	O
reduced	VBD	O	O
hepatic	JJ	O	O
alpha-tocopherol	JJ	O	O
secretion	NN	O	O
.	.	O	O

Third	NNP	O	O
,	,	O	O
ABCA1-RNAi	NNP	O	O
suppressed	VBD	O	O
hepatic	JJ	O	O
alpha-tocopherol	JJ	O	B-PRODUCT-OF
secretion	NN	O	O
.	.	O	O

In	IN	O	O
a	DT	O	O
mouse	NN	O	O
in	IN	O	O
vivo	JJ	O	O
experiment	NN	O	O
,	,	O	O
addition	NN	O	O
of	IN	O	O
1	CD	O	O
%	NN	O	O
probucol	NN	O	O
to	TO	O	O
the	DT	O	O
diet	NN	O	O
decreased	VBD	O	O
plasma	JJ	O	O
alpha-tocopherol	JJ	O	O
concentrations	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
strongly	RB	O	O
suggest	VBP	O	O
that	IN	O	O
ABCA1	NNP	O	B-enzyme
is	VBZ	O	O
substantially	RB	O	O
involved	VBN	O	O
in	IN	O	O
hepatic	JJ	O	O
alpha-tocopherol	JJ	O	B-PRODUCT-OF
secretion	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

A	DT	O	O
study	NN	O	O
has	VBZ	O	O
been	VBN	O	O
made	VBN	O	O
of	IN	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
two	CD	O	O
pools	NNS	O	O
of	IN	O	O
caseinophosphopeptides	NNS	O	O
(	(	O	O
CPPs	NNP	O	O
)	)	O	O
obtained	VBD	O	O
from	IN	O	O
alpha	NNP	O	O
(	(	O	O
s	NN	O	O
)	)	O	O
-	:	O	O
and	CC	O	O
beta-casein	JJ	O	O
(	(	O	O
CN	NNP	O	O
)	)	O	O
fractions	NNS	O	O
,	,	O	O
and	CC	O	O
of	IN	O	O
three	CD	O	O
specific	JJ	O	O
CPPs	NNP	O	O
(	(	O	O
beta-CN	JJ	O	O
(	(	O	O
1-25	JJ	O	O
)	)	O	O
4P	CD	O	O
,	,	O	O
alpha	NNP	O	O
(	(	O	O
s1	NN	O	O
)	)	O	O
-CN	NN	O	O
(	(	O	O
64-74	JJ	O	O
)	)	O	O
4P	CD	O	O
and	CC	O	O
alpha	NNP	O	O
(	(	O	O
s2	NN	O	O
)	)	O	O
-CN	NN	O	O
(	(	O	O
1-19	JJ	O	O
)	)	O	O
4P	CD	O	O
)	)	O	O
,	,	O	O
on	IN	O	O
iron	NN	O	O
bioavailability	NN	O	O
(	(	O	O
ferritin	JJ	O	O
synthesis	NN	O	O
)	)	O	O
and	CC	O	O
zinc	$	O	O
bioavailability	NN	O	O
(	(	O	O
retention	NN	O	O
,	,	O	O
transport	NN	O	O
and	CC	O	O
uptake	NN	O	O
of	IN	O	O
zinc	NN	O	O
)	)	O	O
in	IN	O	O
Caco-2	NNP	O	O
cells	NNS	O	O
.	.	O	O

alpha-CPP	JJ	O	O
and	CC	O	O
beta-CPP	JJ	O	O
pools	NNS	O	O
did	VBD	O	O
not	RB	O	O
improve	VB	O	O
ferritin	NN	O	O
synthesis	NN	O	O
,	,	O	O
but	CC	O	O
the	DT	O	O
three	CD	O	O
specific	JJ	O	O
CPPs	NNP	O	O
showed	VBD	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
ferritin	JJ	O	O
synthesis	NN	O	O
in	IN	O	O
Caco-2	NNP	O	O
cells	NNS	O	O
versus	NN	O	O
iron	NN	O	O
sulphate	NN	O	O
,	,	O	O
beta-CN	JJ	O	O
(	(	O	O
1-25	JJ	O	O
)	)	O	O
4P	CD	O	O
being	VBG	O	O
the	DT	O	O
most	RBS	O	O
effective	JJ	O	O
.	.	O	O

In	IN	O	O
relation	NN	O	O
to	TO	O	O
zinc	VB	O	O
bioavailability	NN	O	O
,	,	O	O
alpha-CPPs	JJ	O	B-enzyme
,	,	O	O
beta-CPPs	JJ	O	B-enzyme
,	,	O	O
alpha	NNP	O	B-enzyme
(	(	O	O
s1	NN	O	O
)	)	O	O
-CN	NN	O	O
(	(	O	O
64-74	JJ	O	O
)	)	O	O
4P	CD	O	O
and	CC	O	O
beta-CN	JJ	O	B-enzyme
(	(	O	O
1-25	JJ	O	O
)	)	O	O
4P	CD	O	O
increased	VBD	O	O
zinc	NN	O	B-SUBSTRATE
uptake	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
this	DT	O	O
increase	NN	O	O
was	VBD	O	O
of	IN	O	O
the	DT	O	O
same	JJ	O	O
order	NN	O	O
as	IN	O	O
the	DT	O	O
increase	NN	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
zinc	NN	O	O
sulphate	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Bisphenol	IN	O	O
A	NNP	O	O
(	(	O	O
BPA	NNP	O	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
estrogenizing	VBG	O	O
endocrine	NN	O	O
disruptor	NN	O	O
compound	NN	O	O
of	IN	O	O
concern	NN	O	O
.	.	O	O

Our	PRP$	O	O
objective	NN	O	O
was	VBD	O	O
to	TO	O	O
test	VB	O	O
whether	IN	O	O
lifelong	JJ	O	O
BPA	NNP	O	O
would	MD	O	O
impact	VB	O	O
cardiac	JJ	O	O
structure/function	NN	O	O
,	,	O	O
calcium	NN	O	O
homeostasis	NN	O	O
protein	NN	O	O
expression	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
DNA	NNP	O	O
methylation	NN	O	O
of	IN	O	O
cardiac	JJ	O	O
genes	NNS	O	O
.	.	O	O

We	PRP	O	O
delivered	VBD	O	O
0.5	CD	O	O
and	CC	O	O
5.0	CD	O	O
g/kg/day	JJ	O	O
BPA	NNP	O	O
lifelong	NN	O	O
from	IN	O	O
gestation	NN	O	O
day	NN	O	O
11	CD	O	O
or	CC	O	O
200	CD	O	O
g/kg/day	NN	O	O
from	IN	O	O
gestation	NN	O	O
day	NN	O	O
11	CD	O	O
to	TO	O	O
postnatal	JJ	O	O
day	NN	O	O
21	CD	O	O
via	IN	O	O
the	DT	O	O
drinking	NN	O	O
water	NN	O	O
to	TO	O	O
C57bl/6n	NNP	O	O
mice	NN	O	O
.	.	O	O

BPA	NNP	O	O
5.0	CD	O	O
males	NNS	O	O
and	CC	O	O
females	NNS	O	O
had	VBD	O	O
increased	VBN	O	O
body	NN	O	O
weight	NN	O	O
,	,	O	O
body	NN	O	O
mass	NN	O	O
index	NN	O	O
,	,	O	O
body	NN	O	O
surface	JJ	O	O
area	NN	O	O
,	,	O	O
and	CC	O	O
adiposity	NN	O	O
.	.	O	O

Echocardiography	NNP	O	O
identified	VBD	O	O
concentric	JJ	O	O
remodeling	VBG	O	O
in	IN	O	O
all	DT	O	O
BPA-treated	JJ	O	O
males	NNS	O	O
.	.	O	O

Systolic	NNP	O	O
and	CC	O	O
diastolic	JJ	O	O
cardiac	JJ	O	O
functions	NNS	O	O
were	VBD	O	O
essentially	RB	O	O
similar	JJ	O	O
,	,	O	O
but	CC	O	O
lifelong	JJ	O	O
BPA	NNP	O	O
enhanced	VBD	O	O
male	NN	O	O
and	CC	O	O
reduced	JJ	O	O
female	JJ	O	O
sex-specific	JJ	O	O
differences	NNS	O	O
in	IN	O	O
velocity	NN	O	O
of	IN	O	O
circumferential	JJ	O	O
shortening	NN	O	O
and	CC	O	O
ascending	VBG	O	O
aorta	JJ	O	O
velocity	NN	O	O
time	NN	O	O
integral	JJ	O	O
.	.	O	O

Diastolic	NNP	O	O
blood	NN	O	O
pressure	NN	O	O
was	VBD	O	O
increased	VBN	O	O
in	IN	O	O
all	DT	O	O
BPA	NNP	O	O
females	NNS	O	O
.	.	O	O

The	DT	O	O
calcium	NN	O	B-SUBSTRATE
homeostasis	NN	O	O
proteins	VBZ	O	O
sarcoendoplasmic	JJ	O	B-enzyme
reticulum	NN	O	I-enzyme
ATPase	NNP	O	O
2a	CD	O	O
(	(	O	O
SERCA2a	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
sodium	JJ	O	B-enzyme
calcium	NN	O	I-enzyme
exchanger-1	NN	O	O
,	,	O	O
phospholamban	NN	O	B-enzyme
(	(	O	O
PLB	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
phospho-PLB	JJ	O	B-enzyme
,	,	O	O
and	CC	O	O
calsequestrin	VB	O	B-enzyme
2	CD	O	I-enzyme
are	VBP	O	O
important	JJ	O	O
for	IN	O	O
contraction	NN	O	O
and	CC	O	O
relaxation	NN	O	O
.	.	O	O

Changes	NNS	O	O
in	IN	O	O
their	PRP$	O	O
expression	NN	O	O
suggest	NN	O	O
increased	VBD	O	O
calcium	NN	O	O
mobility	NN	O	O
in	IN	O	O
males	NNS	O	O
and	CC	O	O
reduced	JJ	O	O
calcium	NN	O	O
mobility	NN	O	O
in	IN	O	O
females	NNS	O	O
supporting	VBG	O	O
the	DT	O	O
cardiac	JJ	O	O
function	NN	O	O
changes	NNS	O	O
.	.	O	O

DNA	NN	O	O
methyltransferase	NN	O	O
3a	CD	O	O
expression	NN	O	O
was	VBD	O	O
increased	VBN	O	O
in	IN	O	O
all	DT	O	O
BPA	NNP	O	O
males	NNS	O	O
and	CC	O	O
BPA	NNP	O	O
0.5	CD	O	O
females	NNS	O	O
and	CC	O	O
reduced	VBN	O	O
in	IN	O	O
BPA	NNP	O	O
200	CD	O	O
females	NNS	O	O
.	.	O	O

Global	JJ	O	O
DNA	NNP	O	O
methylation	NN	O	O
was	VBD	O	O
increased	VBN	O	O
in	IN	O	O
BPA	NNP	O	O
0.5	CD	O	O
males	NNS	O	O
and	CC	O	O
reduced	VBN	O	O
in	IN	O	O
BPA	NNP	O	O
0.5	CD	O	O
females	NNS	O	O
.	.	O	O

BPA	NNP	O	O
induced	VBD	O	O
sex-specific	JJ	O	O
altered	JJ	O	O
DNA	NNP	O	O
methylation	NN	O	O
in	IN	O	O
specific	JJ	O	O
CpG	NNP	O	O
pairs	NN	O	O
in	IN	O	O
the	DT	O	O
calsequestrin	NN	O	O
2	CD	O	O
CpG	NNP	O	O
island	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
continual	JJ	O	O
exposure	NN	O	O
to	TO	O	O
BPA	NNP	O	O
impacts	NNS	O	O
cardiac	JJ	O	O
structure/function	NN	O	O
,	,	O	O
protein	JJ	O	O
expression	NN	O	O
,	,	O	O
and	CC	O	O
epigenetic	JJ	O	O
DNA	NNP	O	O
methylation	NN	O	O
marks	NNS	O	O
in	IN	O	O
males	NNS	O	O
and	CC	O	O
females	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Ketamine	NNP	O	B-SUBSTRATE
is	VBZ	O	O
primarily	RB	O	O
metabolized	VBN	O	O
to	TO	O	O
norketamine	VB	O	O
by	IN	O	O
hepatic	JJ	O	O
cytochrome	NN	O	B-enzyme
P450	NNP	O	I-enzyme
(	(	O	O
CYP	NNP	O	O
)	)	O	O
2B6	CD	O	O
and	CC	O	O
CYP3A4-mediated	JJ	O	O
N-demethylation	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
relative	JJ	O	O
contribution	NN	O	O
from	IN	O	O
each	DT	O	O
enzyme	NN	O	O
remains	VBZ	O	O
controversial	JJ	O	O
.	.	O	O

The	DT	O	O
CYP2B6	NNP	O	B-enzyme
*	NNP	O	O
6	CD	O	O
allele	NN	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
reduced	JJ	O	O
enzyme	JJ	O	O
expression	NN	O	O
and	CC	O	O
activity	NN	O	O
that	WDT	O	O
may	MD	O	O
lead	VB	O	O
to	TO	O	O
interindividual	JJ	O	O
variability	NN	O	O
in	IN	O	O
ketamine	JJ	O	B-SUBSTRATE
metabolism	NN	O	O
.	.	O	O

We	PRP	O	O
examined	VBD	O	O
the	DT	O	O
N-demethylation	NN	O	O
of	IN	O	O
individual	JJ	O	O
ketamine	NN	O	B-SUBSTRATE
enantiomers	NNS	O	O
using	VBG	O	O
human	JJ	O	O
liver	NN	O	O
microsomes	NNS	O	O
(	(	O	O
HLMs	NNP	O	O
)	)	O	O
genotyped	VBD	O	O
for	IN	O	O
the	DT	O	O
CYP2B6	NNP	O	B-enzyme
*	NNP	O	O
6	CD	O	O
allele	NN	O	O
,	,	O	O
insect	VBP	O	O
cell	NN	O	O
expressed	VBN	O	O
recombinant	JJ	O	O
CYP2B6	NNP	O	O
and	CC	O	O
CYP3A4	NNP	O	O
enzymes	NNS	O	O
and	CC	O	O
COS-1	NNP	O	O
cell	NN	O	O
expressed	VBD	O	O
recombinant	JJ	O	O
CYP2B6.1	NNP	O	O
and	CC	O	O
CYP2B6.6	NNP	O	O
protein	NN	O	O
variant	NN	O	O
.	.	O	O

Effects	NNS	O	O
of	IN	O	O
CYP-selective	JJ	O	O
inhibitors	NNS	O	O
on	IN	O	O
norketamine	JJ	O	O
formation	NN	O	O
were	VBD	O	O
also	RB	O	O
determined	VBN	O	O
in	IN	O	O
HLMs	NNP	O	O
.	.	O	O

The	DT	O	O
two-enzyme	JJ	O	O
Michaelis-Menten	NNP	O	O
model	NN	O	O
best	RB	O	O
fitted	VBD	O	O
the	DT	O	O
HLM	NNP	O	O
kinetic	JJ	O	O
data	NNS	O	O
.	.	O	O

The	DT	O	O
Km	NNP	O	O
value	NN	O	O
for	IN	O	O
the	DT	O	O
high	JJ	O	O
affinity	NN	O	O
enzyme	NN	O	O
and	CC	O	O
the	DT	O	O
low	JJ	O	O
affinity	NN	O	O
enzyme	NN	O	O
were	VBD	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
for	IN	O	O
the	DT	O	O
expressed	VBN	O	O
CYP2B6	NNP	O	O
and	CC	O	O
CYP3A4	NNP	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

The	DT	O	O
intrinsic	JJ	O	O
clearance	NN	O	O
for	IN	O	O
both	DT	O	O
ketamine	JJ	O	B-SUBSTRATE
enantiomers	NNS	O	O
by	IN	O	O
the	DT	O	O
high	JJ	O	O
affinity	NN	O	O
enzyme	NN	O	O
in	IN	O	O
HLMs	NNP	O	O
with	IN	O	O
CYP2B6	NNP	O	B-enzyme
*	NNP	O	O
1/	CD	O	O
*	VBD	O	O
1	CD	O	O
genotype	NN	O	O
were	VBD	O	O
at	IN	O	O
least	JJS	O	O
2-fold	JJ	O	O
and	CC	O	O
6-fold	JJ	O	O
higher	JJR	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
than	IN	O	O
those	DT	O	O
for	IN	O	O
CYP2B6	NNP	O	O
*	NNP	O	O
1/	CD	O	O
*	VBD	O	O
6	CD	O	O
genotype	NN	O	O
and	CC	O	O
CYP2B6	NNP	O	O
*	NNP	O	O
6/	CD	O	O
*	VBD	O	O
6	CD	O	O
genotype	NN	O	O
.	.	O	O

The	DT	O	O
Vmax	NNP	O	O
and	CC	O	O
Km	NNP	O	O
values	NNS	O	O
for	IN	O	O
CYP2B6.1	NNP	O	O
were	VBD	O	O
approximately	RB	O	O
160	CD	O	O
%	NN	O	O
and	CC	O	O
70	CD	O	O
%	NN	O	O
of	IN	O	O
those	DT	O	O
for	IN	O	O
CYP2B6.6	NNP	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

ThioTEPA	NNP	O	O
(	(	O	O
CYP2B6	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
25	CD	O	O
muM	NN	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
monoclonal	JJ	O	O
antibody	NN	O	O
against	IN	O	O
CYP2B6	NNP	O	O
but	CC	O	O
not	RB	O	O
troleandomycin	VB	O	O
(	(	O	O
CYP3A4	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
25	CD	O	O
muM	NN	O	O
)	)	O	O
or	CC	O	O
the	DT	O	O
monoclonal	JJ	O	O
antibody	NN	O	O
against	IN	O	O
CYP3A4	NNP	O	O
inhibited	JJ	O	O
ketamine	NN	O	O
N-demethylation	NN	O	O
at	IN	O	O
clinically	RB	O	O
relevant	JJ	O	O
concentrations	NNS	O	O
.	.	O	O

The	DT	O	O
degree	NN	O	O
of	IN	O	O
inhibition	NN	O	O
was	VBD	O	O
significantly	RB	O	O
reduced	VBN	O	O
in	IN	O	O
HLMs	NNP	O	O
with	IN	O	O
the	DT	O	O
CYP2B6	NNP	O	O
*	NNP	O	O
6	CD	O	O
allele	NN	O	O
(	(	O	O
gene-dose	JJ	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
a	DT	O	O
major	JJ	O	O
role	NN	O	O
of	IN	O	O
CYP2B6	NNP	O	B-enzyme
in	IN	O	O
ketamine	JJ	O	B-SUBSTRATE
N-demethylation	NN	O	O
in	IN	O	O
vitro	NN	O	O
and	CC	O	O
a	DT	O	O
significant	JJ	O	O
impact	NN	O	O
of	IN	O	O
the	DT	O	O
CYP2B6	NNP	O	B-enzyme
*	NNP	O	O
6	CD	O	O
allele	NN	O	O
on	IN	O	O
enzyme-ketamine	JJ	O	O
binding	NN	O	O
and	CC	O	O
catalytic	JJ	O	O
activity	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Introduction	NN	O	O
:	:	O	O
5-Lipoxygenase	JJ	O	B-enzyme
(	(	O	O
5-LO	JJ	O	B-enzyme
)	)	O	O
is	VBZ	O	O
a	DT	O	O
crucial	JJ	O	O
enzyme	NN	O	O
of	IN	O	O
the	DT	O	O
arachidonic	JJ	O	B-SUBSTRATE
acid	NN	O	I-SUBSTRATE
(	(	O	O
AA	NNP	O	O
)	)	O	O
cascade	NN	O	O
and	CC	O	O
catalyzes	VBZ	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
bioactive	JJ	O	O
leukotrienes	NNS	O	O
(	(	O	O
LTs	NNP	O	O
)	)	O	O
with	IN	O	O
the	DT	O	O
help	NN	O	O
of	IN	O	O
FLAP	NNP	O	O
,	,	O	O
the	DT	O	O
5-LO-activating	JJ	O	O
protein	NN	O	O
.	.	O	O

LTs	NNP	O	O
are	VBP	O	O
inflammatory	JJ	O	O
mediators	NNS	O	O
playing	VBG	O	O
a	DT	O	O
pathophysiological	JJ	O	O
role	NN	O	O
in	IN	O	O
different	JJ	O	O
diseases	NNS	O	O
like	IN	O	O
asthma	NN	O	O
,	,	O	O
allergic	JJ	O	O
rhinitis	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
cardiovascular	JJ	O	O
diseases	NNS	O	O
and	CC	O	O
certain	JJ	O	O
types	NNS	O	O
of	IN	O	O
cancer	NN	O	O
.	.	O	O

With	IN	O	O
the	DT	O	O
rising	VBG	O	O
number	NN	O	O
of	IN	O	O
indications	NNS	O	O
for	IN	O	O
anti-LT	JJ	O	O
therapy	NN	O	O
,	,	O	O
5-LO	JJ	O	O
inhibitor	NN	O	O
drug	NN	O	O
development	NN	O	O
becomes	VBZ	O	O
increasingly	RB	O	O
important	JJ	O	O
.	.	O	O

Areas	RB	O	O
covered	VBN	O	O
:	:	O	O
Here	RB	O	O
,	,	O	O
both	DT	O	O
recent	JJ	O	O
findings	NNS	O	O
regarding	VBG	O	O
the	DT	O	O
pathophysiological	JJ	O	O
role	NN	O	O
of	IN	O	O
5-LO	JJ	O	O
and	CC	O	O
the	DT	O	O
patents	NNS	O	O
claimed	VBD	O	O
for	IN	O	O
5-LO	JJ	O	O
inhibitors	NNS	O	O
are	VBP	O	O
discussed	VBN	O	O
.	.	O	O

Focusing	VBG	O	O
on	IN	O	O
direct	JJ	O	O
inhibitors	NNS	O	O
,	,	O	O
several	JJ	O	O
patents	NNS	O	O
disclosing	VBG	O	O
FLAP	NNP	O	O
antagonists	NNS	O	O
are	VBP	O	O
also	RB	O	O
subject	JJ	O	O
of	IN	O	O
this	DT	O	O
review	NN	O	O
.	.	O	O

Novel	NNP	O	O
compounds	NNS	O	O
include	VBP	O	O
1,5-diarylpyrazoles	NNS	O	O
,	,	O	O
indolizines	NNS	O	O
and	CC	O	O
indoles	NNS	O	O
and	CC	O	O
several	JJ	O	O
natural	JJ	O	O
product	NN	O	O
extracts	NNS	O	O
.	.	O	O

Expert	JJ	O	O
opinion	NN	O	O
:	:	O	O
Evaluation	NN	O	O
of	IN	O	O
the	DT	O	O
patent	NN	O	O
activities	NNS	O	O
revealed	VBD	O	O
only	RB	O	O
quite	RB	O	O
moderate	JJ	O	O
action	NN	O	O
.	.	O	O

Nevertheless	RB	O	O
,	,	O	O
several	JJ	O	O
auspicious	JJ	O	O
drug-like	JJ	O	O
molecules	NNS	O	O
were	VBD	O	O
disclosed	VBN	O	O
.	.	O	O

It	PRP	O	O
seems	VBZ	O	O
that	IN	O	O
in	IN	O	O
the	DT	O	O
near	JJ	O	O
future	NN	O	O
,	,	O	O
FLAP	NNP	O	O
inhibitors	NNS	O	O
can	MD	O	O
be	VB	O	O
expected	VBN	O	O
to	TO	O	O
enter	VB	O	O
the	DT	O	O
market	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
asthma	NN	O	O
.	.	O	O

With	IN	O	O
the	DT	O	O
resolved	JJ	O	O
structure	NN	O	O
of	IN	O	O
5-LO	JJ	O	O
,	,	O	O
structure-based	JJ	O	O
drug	NN	O	O
design	NN	O	O
is	VBZ	O	O
now	RB	O	O
applicable	JJ	O	O
.	.	O	O

Together	RB	O	O
with	IN	O	O
the	DT	O	O
identification	NN	O	O
of	IN	O	O
downstream	NN	O	O
enzyme	NN	O	O
inhibitors	NNS	O	O
and	CC	O	O
dual-targeting	JJ	O	O
drugs	NNS	O	O
within	IN	O	O
the	DT	O	O
AA	NNP	O	O
cascade	NN	O	O
,	,	O	O
several	JJ	O	O
tools	NNS	O	O
are	VBP	O	O
at	IN	O	O
hand	NN	O	O
to	TO	O	O
cope	VB	O	O
with	IN	O	O
5-LOs	JJ	O	O
increasing	VBG	O	O
pathophysiological	JJ	O	O
roles	NNS	O	O
.	.	O	O
